Durable stent graft with tapered struts and stable delivery methods and devices

Information

  • Patent Grant
  • 8992595
  • Patent Number
    8,992,595
  • Date Filed
    Wednesday, March 13, 2013
    11 years ago
  • Date Issued
    Tuesday, March 31, 2015
    9 years ago
Abstract
Some embodiments relate in part to endovascular prostheses and methods of deploying same. Embodiments may be directed more specifically to stent grafts and methods of making and deploying same within the body of a patient. Stent embodiments may include tapered struts for an even distribution of strain. Stent embodiments may also include portions which are enlarged in a circumferential direction which may be configured to stabilize the stent in a constrained state.
Description
FIELD OF THE INVENTION

Some embodiments relate in part to endovascular prostheses and methods of deploying same. Embodiments may be directed more specifically to stent grafts and methods of making and deploying same within the body of a patient.


BACKGROUND

An aneurysm is a medical condition indicated generally by an expansion and weakening of the wall of an artery of a patient. Aneurysms can develop at various sites within a patient's body. Thoracic aortic aneurysms (TAAs) or abdominal aortic aneurysms (AAAs) are manifested by an expansion and weakening of the aorta which is a serious and life threatening condition for which intervention is generally indicated. Existing methods of treating aneurysms include invasive surgical procedures with graft replacement of the affected vessel or body lumen or reinforcement of the vessel with a graft.


Surgical procedures to treat aortic aneurysms can have relatively high morbidity and mortality rates due to the risk factors inherent to surgical repair of this disease as well as long hospital stays and painful recoveries. This is especially true for surgical repair of TAAs, which is generally regarded as involving higher risk and more difficulty when compared to surgical repair of AAAs. An example of a surgical procedure involving repair of a AAA is described in a book titled Surgical Treatment of Aortic Aneurysms by Denton A. Cooley, M.D., published in 1986 by W. B. Saunders Company.


Due to the inherent risks and complexities of surgical repair of aortic aneurysms, endovascular repair has become a widely-used alternative therapy, most notably in treating AAAs. Early work in this field is exemplified by Lawrence, Jr. et al. in “Percutaneous Endovascular Graft: Experimental Evaluation”, Radiology (May 1987) and by Mirich et al. in “Percutaneously Placed Endovascular Grafts for Aortic Aneurysms: Feasibility Study,” Radiology (March 1989). Commercially available endoprostheses for the endovascular treatment of AAAs include the AneuRx® stent graft manufactured by Medtronic, Inc. of Minneapolis, Minn., the Zenith® stent graft system sold by Cook, Inc. of Bloomington, Ind., the PowerLink® stent-graft system manufactured by Endologix, Inc. of Irvine, Calif., and the Excluder® stent graft system manufactured by W.L. Gore & Associates, Inc. of Newark, Del. A commercially available stent graft for the treatment of TAAs is the TAG™ system manufactured by W.L. Gore & Associates, Inc.


When deploying devices by catheter or other suitable instrument, it is advantageous to have a flexible and low profile stent graft and delivery system for passage through the various guiding catheters as well as the patient's sometimes tortuous anatomy. Many of the existing endovascular devices and methods for treatment of aneurysms, while representing significant advancement over previous devices and methods, use systems having relatively large transverse profiles, often up to 24 French. Also, such existing systems have greater than desired lateral stiffness, which can complicate the delivery process. In addition, the sizing of stent grafts may be important to achieve a favorable clinical result. In order to properly size a stent graft, the treating facility typically must maintain a large and expensive inventory of stent grafts in order to accommodate the varied sizes of patient vessels due to varied patient sizes and vessel morphologies. Alternatively, intervention may be delayed while awaiting custom size stent grafts to be manufactured and sent to the treating facility. As such, minimally invasive endovascular treatment of aneurysms is not available for many patients that would benefit from such a procedure and can be more difficult to carry out for those patients for whom the procedure is indicated.


What have been needed are stent graft systems and methods that are adaptable to a wide range of patient anatomies and that can be safely and reliably deployed using a flexible low profile system.


SUMMARY

Some embodiments are directed to a self-expanding cylindrical stent which has a constrained state and a relaxed expanded state. The stent may also include a longitudinal axis, a proximal end, a distal end, and a plurality of resilient struts configured to exert an outward radial force in the constrained state. At least one of the resilient struts may include a longitudinal section which is enlarged in a circumferential orientation relative to a longitudinal axis of the stent and configured to stabilize the at least one strut relative to the position of adjacent struts while the stent is in a constrained state. At least some of the enlarged longitudinal sections may be in axial alignment with each other. In some cases, the enlarged longitudinal sections of the struts may be enlarged in one transverse dimension of the struts. In some cases, the enlarged longitudinal sections may be enlarged along a circumferential direction about the longitudinal axis of the stent and the struts may have a substantially constant thickness in a radial direction relative to the longitudinal axis of the stent. The enlarged longitudinal section may have an enlarged transverse dimension that is about 1.5 times to about 3 times the nominal transverse dimension of the strut in a direction of the enlargement for some embodiments.


Certain embodiments are directed to an endovascular stent graft, having a main body portion including at least one tubular portion made from at least one layer of flexible material and a self-expanding cylindrical stent which has a constrained state and a relaxed expanded state. The stent may also include a longitudinal axis, a proximal end, a distal end, a plurality of resilient struts configured to exert an outward radial force in the constrained state. At least one of the resilient struts may include a longitudinal section which is enlarged in a circumferential orientation relative to a longitudinal axis of the stent and configured to stabilize the at least one strut relative to the position of adjacent struts while the stent is in a constrained state. All resilient struts may include a longitudinal section which is enlarged in a circumferential orientation relative to a longitudinal axis of the stent and configured to stabilize at least one strut relative to the position of adjacent struts while the stent is in a constrained state in some embodiments. In some cases, at least some of the enlarged longitudinal sections may be in axial alignment with each other. In some instances, the enlarged longitudinal sections of the struts may be enlarged in one transverse dimension of the struts. In some instances, the enlarged longitudinal sections may be enlarged along a circumferential direction about the longitudinal axis of the stent and the struts may have a substantially constant thickness in a radial direction relative to the longitudinal axis of the stent. The enlarged longitudinal section may have an enlarged transverse dimension that is about 1.5 times to about 3 times the nominal transverse dimension of the strut in a direction of the enlargement in some embodiments.


Some embodiments are directed to a method of loading a delivery catheter system with an endovascular stent graft. The endovascular stent graft may have a main body portion including at least one tubular portion made from at least one layer of flexible material, and a self-expanding cylindrical stent which has a constrained state and a relaxed expanded state. The self-expanding cylindrical stent may include a longitudinal axis, a proximal end, a distal end, a plurality of resilient struts configured to exert an outward radial force in the constrained state. At least one of the resilient struts may include a longitudinal section which is enlarged in a circumferential orientation relative to a longitudinal axis of the stent and configured to separate and stabilize the at least one strut relative to the position of adjacent struts while the stent is in a constrained state. In some cases, the self-expanding cylindrical stent of the stent graft may be constrained about a bushing of the delivery system such that the enlarged longitudinal section of the at least one resilient strut stabilizes the position of the at least one strut relative to the position of adjacent struts in the constrained state. In some instances, the stent may be releasably secured in the constrained stabilized state.


Some embodiments of an endovascular stent graft may include a main body portion having at least one tubular portion made from at least one layer of flexible material and a self-expanding anchor member. The self-expanding anchor member may include a constrained state, a relaxed expanded state, a proximal stent portion, and a distal stent portion. In some cases, the endovascular stent graft may be configured such that a proximal end of the distal stent portion is secured to a distal end of the proximal stent portion and a distal end of the distal stent portion is secured to a proximal end of the main body portion. The endovascular stent graft may also be configured such that the axial length of the self-expanding anchor member as a whole divided by the axial length of the proximal stent portion is a ratio of about 1.75 to about 2.0.


Some embodiments of a self-expanding anchor member include a constrained state, a relaxed expanded state, a proximal stent portion, and a distal stent portion. In some cases, the anchor member may be configured such that a proximal end of the distal stent portion is secured to a distal end of the proximal stent portion and the axial length of the self-expanding anchor member as a whole divided by the axial length of the proximal stent portion is a ratio of about 1.75 to about 2.0.


Some embodiments of an endovascular stent graft may include a main body portion including at least one tubular portion made from at least one layer of flexible material and a self-expanding cylindrical stent which has a constrained state and a relaxed expanded state. The self-expanding cylindrical stent may include a longitudinal axis, a proximal end, a distal end, and a plurality of resilient struts configured to exert an outward radial force in the constrained state. At least one of the resilient struts may have a longitudinal section which is enlarged in a circumferential orientation relative to a longitudinal axis of the stent and be configured to stabilize the at least one strut relative to the position of adjacent struts while the stent is in a constrained state. For such an embodiment, all of the resilient struts of the stent may include a longitudinal section which is enlarged in a circumferential orientation relative to a longitudinal axis of the stent and be configured to stabilize the at least one strut relative to the position of adjacent struts while the stent is in a constrained state. In some cases at least some of the enlarged longitudinal sections may be in axial alignment with each other. In some instances, the enlarged longitudinal sections of the struts may be enlarged in one transverse dimension of the struts or the enlarged longitudinal sections may be enlarged along a circumferential direction about the longitudinal axis of the stent and the struts may have a substantially constant thickness in a radial direction relative to the longitudinal axis of the stent. For some embodiments, the enlarged longitudinal section may have an enlarged transverse dimension that is about 1.5 times to about 3 times the nominal transverse dimension of the strut in a direction of the enlargement. In some cases, the enlarged longitudinal section includes an undulating configuration of the nominal strut or an oval enlargement of the nominal strut. In some instances, each strut of the stent may include an enlarged longitudinal section with only one enlarged longitudinal section or an enlarged longitudinal section with a plurality of enlarged longitudinal sections. For some embodiments, the struts having enlarged longitudinal sections may be disposed in a substantially longitudinal orientation between the proximal end and distal end of the stent when the stent is in the constrained state. In some cases, the struts may be disposed in an undulating pattern. In some instances, the self-expanding cylindrical stent of the stent graft may include a superelastic alloy such as NiTi alloy.


Certain embodiments are described further in the following description, examples, claims and drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates an elevation view of an embodiment of an endoluminal prosthesis in the form of a stent graft for treatment of a patient's vessel.



FIG. 1A is an enlarged view of the encircled portion 1A of FIG. 1 including a proximal self-expanding stent member and proximal connector ring of the stent graft embodiment of FIG. 1.



FIG. 2 illustrates the stent graft embodiment of FIG. 1 in a constrained configuration disposed on a distal section of a delivery catheter within a lumen of a patient's vessel.



FIG. 3 shows an enlarged view of the encircled portion 3 of the stent graft of FIG. 2 including the proximal self-expanding stent member in a constrained configuration but without the constraining releasable belts for clarity of illustration.



FIG. 3A is a transverse cross sectional view of the proximal self-expanding stent member and delivery catheter system of FIG. 3 taken along lines 3A-3A of FIG. 3.



FIG. 4 illustrates the stent graft of FIG. 2 in a deployed unconstrained state.



FIG. 5 is a schematic view of an embodiment of a section of a stent that illustrates features of struts of the stent.


FIGS. 6A and 6AA illustrate paired transverse cross section views of a strut embodiment of FIG. 5 taken along the lines 6A-6A and 6AA-6AA of FIG. 5.


FIGS. 6B and 6BB illustrate paired transverse cross section views of another strut embodiment of FIG. 5.


FIGS. 6C and 6CC illustrate paired transverse cross section views of another strut embodiment of FIG. 5.


FIGS. 6D and 6DD illustrate paired transverse cross section views of another strut embodiment of FIG. 5.


FIGS. 6E and 6EE illustrate paired transverse cross section views of another strut embodiment of FIG. 5.



FIG. 7A illustrates a strut embodiment in longitudinal section taken along lines 7A-7A of the stent embodiment in FIG. 5.



FIG. 7B illustrates another strut embodiment in longitudinal section.



FIG. 7C illustrates another strut embodiment in longitudinal section.



FIG. 8 illustrates a portion of an embodiment of a stent including struts having a stepped taper configuration.



FIG. 9 illustrates a portion of an embodiment of a stent including struts having a continuous taper, barbs, and tuck pads with tuck slots.



FIG. 10A illustrates a portion of a cylindrical stent embodiment in a constrained configuration including struts having coaxial enlarged portion embodiments.



FIG. 10B illustrates a portion of a cylindrical stent embodiment in a constrained configuration including struts having coaxial enlarged portion embodiments.



FIG. 10C illustrates a portion of a cylindrical stent embodiment in a constrained configuration including struts having undulating deflected portions configured to physically separate adjacent struts in a circumferential direction.



FIG. 11 illustrates a portion of a cylindrical stent embodiment in a constrained configuration shown flattened including struts having coaxial enlarged portion embodiments and undulating deflected portions.



FIG. 12 is a transverse cross section view of the stent portion of FIG. 11 taken along lines 12-12 of FIG. 11.



FIG. 13 is an elevation view of a bifurcated stent graft embodiment.



FIG. 14 illustrates and embodiment of the stent graft of FIG. 13 partially deployed within a patient's aorta.



FIG. 15 is a perspective view of a proximal anchor member embodiment.



FIG. 16 is an elevation view of a cut away portion of the proximal anchor member embodiment of FIG. 15.



FIG. 17 is an elevation view of a cut away portion of the proximal anchor member embodiment of FIG. 16.



FIG. 18 shows a distal portion of the cut away portion of the proximal anchor member of FIG. 16.



FIG. 19 is an enlarged view of the encircled portion 19-19 in FIG. 18.





The drawings illustrate embodiments of the invention and are not limiting. For clarity and ease of illustration, the drawings are not made to scale and, in some instances, various aspects may be shown exaggerated or enlarged to facilitate an understanding of particular embodiments.


DETAILED DESCRIPTION

Embodiments of the invention are directed generally to methods and devices for treatment of fluid flow vessels with the body of a patient. Treatment of blood vessels may be specifically indicated for some embodiments, and, more specifically, treatment of aneurysms, such as abdominal aortic aneurysms. Devices for such treatment modalities may include stents, grafts and stent graft assemblies that include at least one stent secured to a graft member.


For some embodiments, the modular graft assembly may be bifurcated for treatment of an abdominal aortic aneurysm. Such a graft assembly embodiment may include a bifurcated main body member, an ipsilateral graft extension and contralateral graft extension. The main body may have a wall portion that binds a main fluid flow lumen disposed therein. An ipsilateral leg of the main body may have an ipsilateral port and an ipsilateral fluid flow lumen that is in fluid communication with the main fluid flow lumen and the ipsilateral port. A contralateral leg of the main body may have a contralateral port and a contralateral fluid flow lumen that is in fluid communication with the main fluid flow lumen and the contralateral port. The main body, ipsilateral leg, and contralateral leg may form a bifurcated “Y” shaped configuration.


For some bifurcated embodiments, the main fluid flow lumen of the main body generally may have a larger transverse dimension and area than a transverse dimension and area of either of the fluid flow lumens of the ipsilateral leg or contralateral leg. A proximal anchor member may be disposed at a proximal end of the main body. The proximal anchor member may include a proximal self-expanding stent that is formed from an elongate element having a generally serpentine shape with four crowns or apices at either end. Each proximal apex or crown of the proximal stent may be coupled to alternating distal crowns or apices of an eight crown distal self-expanding stent. The distal self-expanding stent may be formed from an elongate element having a generally serpentine shape. A distal end of the distal stent may be mechanically coupled to a connector ring which may be embedded in graft material of the proximal end of the main body, or directly coupled to perforations in the proximal edge region of the main body. Embodiments of the connector ring may be generally circular in shape having regular undulations about the circumference that may be substantially sinusoidal in shape. The proximal stent may include outwardly extending barbs, that may be integrally formed with the struts of the stent for some embodiments, having sharp tissue penetrating tips that are configured to penetrate into tissue of an inside surface of a lumen within which the proximal stent is deployed in an expanded state. Although the proximal anchor member may include self-expanding stents, similar stents may be used that are configured to be inelastically expanded with outward radial pressure as might be generated by the expansion of an expandable balloon from within either or both stents. The connector ring coupled to the proximal stent may also be inelastically expandable.


With regard to graft embodiments discussed herein, such as graft assembly, and components thereof, as well as graft extensions and, the term “proximal” refers to a location towards a patient's heart and the term “distal” refers to a location away from the patient's heart. With regard to delivery system catheters and components thereof discussed herein, the term “distal” refers to a location that is disposed away from an operator who is using the catheter and the term “proximal” refers to a location towards the operator.



FIGS. 1-4 illustrate an embodiment of a stent graft assembly 150 which may include a main graft member or main body portion 152 which is not bifurcated. The main body 152 may be tubular in shape and have a wall portion 153 that bounds a main fluid flow lumen 155 disposed therein. The main body 152 may include a proximal end 154, a distal end 156 and an inflatable portion 158. The main body 152 of the stent graft assembly 150 may include at least one flexible layer of material such as PTFE, polymer meshes, composites of same or the like. A proximal anchor member or stent may be disposed at the proximal end 154 of the main body 152. The proximal anchor member embodiment shown in FIG. 1 includes a single proximal self-expanding stent member 160 disposed about a proximal end 154 of the main body 152. In some embodiments, the proximal self-expanding stent member 160 may be formed from an elongate element having a generally serpentine shape with eight crowns or apices at either end. A distal end 162 of the proximal self-expanding stent member 160 may be mechanically coupled to a proximal connector ring 164 which may be embedded in graft material generally about the proximal end 154 of the main body 152, or directly coupled to perforations in the proximal end 154 region of the main body 152.


A distal self-expanding stent member 170 may be disposed at the distal end 156 of the main body 152 and may be configured to engage an interior luminal surface 132 within the patient's vasculature 130. The distal self-expanding stent member 170 shown in FIG. 1 includes a single self-expanding stent member disposed along the distal end 156 of the main body 152 of the stent graft assembly 152. The distal self-expanding stent member 170 may be formed from a resilient elongate element having a generally serpentine shape with eight crowns or apices at either end. A proximal end 172 of the distal self-expanding stent member 170 may be mechanically coupled to a distal connector ring 174 which may be embedded in graft material generally about the distal end 156 of the main body 152, or directly coupled to perforations in the distal end 156 region of the main body 152.


Embodiments of either the proximal connector ring 164 or distal connector ring 174 may be generally circular or cylindrical in shape with regular undulations about the circumference that may be substantially sinusoidal or zig-zag in shape. Some embodiments of either the proximal or distal self-expanding stent members 160, 170 may include outwardly extending barbs 165 (see FIG. 1A). Such barbs 165 may be integrally formed with the struts 168 of either the proximal self-expanding stent member 160 or distal self-expanding member 170. Furthermore, the barbs 165 may have sharp tissue penetrating tips that may be configured to penetrate into tissue of an inside surface of a lumen within which either the proximal self-expanding stent member 160 or distal self-expanding member 170 may be deployed into an expanded state.


Although the proximal and distal self-expanding stent members 160 and 170 of the stent graft 150 has generally been described as including self-expanding stents, the proximal and distal self-expanding stent members 160 and 170 may also include similar stents that are configured to be inelastically expanded with outward radial pressure as might be generated by the expansion of an expandable balloon from within either the proximal self-expanding stent member 160 or distal self-expanding stent member 170. Additionally, at least one of the proximal self-expanding stent member 160 and distal self-expanding stent member 170 may be made from or include a superelastic alloy, such as NiTi alloy.


The stent graft 150 may further include an optional inflation conduit (not shown) which may serve as a fill manifold for inflation of the inflatable portion 158 of the stent graft 150. The inflation conduit may include a distal end with an inflation port in fluid communication with an exterior portion of the main body 152 and extending from the distal end 156 into an interior volume of the inflatable portion 158 of the stent graft 150.


Some embodiments of the stent graft 150 may include radiopaque markers 116 that may be used to facilitate alignment of the stent graft 150. A radiopaque marker 116 configuration and imaging system may be used for alignment during positioning of the stent graft 150 in a patient. FIG. 1A illustrates an enlarged view of a portion of the stent graft 150 with portions of the stent graft 150 not shown for clarity of illustration. The stent graft 150 embodiment shown in FIG. 1A illustrates the proximal end 154 of the main body 152, the proximal self-expanding stent member 160, and a plurality of radiopaque markers 116 disposed about a circumference of a distal end 162 of the proximal self-expanding stent member 160. Furthermore, the plurality of radiopaque markers 116 may include helically wound wire members which may be disposed about connector members 216, as shown in FIG. 1A. In general, the connector members 216 may be configured to mechanically couple the proximal self-expanding stent member 160 to the proximal connector ring 164 disposed within the proximal end 154 of the main body 152 of the stent graft 150. Some embodiments of the stent graft 150 may additionally or alternatively include a plurality of radiopaque markers 116 circumferentially disposed about a tubular portion of the endovascular stent graft 150. For example, the radiopaque markers 116 may lie in a plane that is substantially orthogonal or parallel to a longitudinal axis 186 of the tubular main body 152 of the stent graft 150. Additionally, the distal self-expanding member 170 may include one or more radiopaque markers 116.


Furthermore, any number of features may be incorporated into the stent graft 150 which may enable detection of all or part of the stent graft 150 under fluoroscopy or other suitable forms of imaging. For example, in general, the radiopaque markers 116, or other detection features, may be used to facilitate orthogonal orientation of the imaging axis or view. Once a substantially orthogonal view angle is achieved, an accurate axial position of the partially deployed stent graft 150 relative to the patient's vasculature may be achieved, avoiding parallax, ensuring precise placement of the stent graft 150 relative to significant branch vessels or other anatomic reference points. Parallax in some circumstances may cause error in axial placement of the stent graft 150 relative to the intended target site. Accurate positioning may be achieved with axial movement and adjustment of the stent graft 150 by manual manipulation of a proximal portion of the delivery catheter 100.


As shown in FIG. 2, the stent graft 150 may be positioned such that the proximal end 154 of the main body 152 of the stent graft 150 is aligned distal of the ostium of the renal arteries. Once the delivery catheter 100 system has been positioned at the treatment site an outer sheath 102 of the delivery catheter 100 may be proximally retracted. Though the outer sheath 102 may have been proximally retracted, thus exposing the stent graft 150, the stent graft 150 may remain in a partially constrained state with the proximal self-expanding stent member 160 restrained by a pair of proximal releasable belts 104 and 106 releasably disposed about the proximal self-expanding stent member 160. The distal self-expanding stent member 170 may be constrained by another set of distal releasable belts 108 and 110 which may be releasably disposed about the distal self-expanding stent member 170.


Each of the releasable belts 104, 106, 108 and 110 may be configured to be independently released by retraction of one or more respective release wires 120. Release wires 120 may be disposed within an end loop or loops of the releasable belts 104, 106, 108 and 110 with the one or more release wires 120 holding the loops in fixed relation to each other. For this arrangement, retraction of one or more release wires 120 from the end loops releases the loops to allow them to move relative to each other which in turn removes the constraint of the belt members 104, 106, 108 and 110 about the respective proximal and distal self-expanding stent members 160 and 170. After at least partial deployment of the proximal stent member 160, finalizing the axial position of the stent graft 150 relative to the anatomy of the patient's vasculature 130 and treatment site may then be made. The axial positioning may be accomplished in some embodiments with the use of one or more radiopaque marker devices 116, as described above. Once the partially radially constrained stent graft 150 is axially aligned, the proximal self-expanding stent member 160 may then be fully deployed in order to engage and become secured to the luminal wall or interior luminal surface 132 of the patient's vasculature 130, as shown by way of example in FIG. 4. Once the proximal anchor member 160 is fully deployed, the inflatable portion 158 of the stent graft 150, including the network of inflatable channels, may be inflated with a fill material. For some embodiments, the network of inflatable channels may be filled from a desired site within the inflatable portion 158. More specifically, the inflatable portion 158 may be inflated with fill material from a proximal end 154 of the main body 152.


The proximal self-expanding stent member 160 may be disposed at and secured to a proximal end 154 of the main body 152. For example, the proximal self-expanding stent member 160 may have a first self-expanding stent member 200 secured to a second self-expanding stent member 202. Both the first and second self-expanding stent members 200 and 202 may have a somewhat tubular shape and may be secured together by one or more struts 168. Some embodiments of the struts 168 may have one or more cross sectional areas 169 that vary along the length of the strut 168. Such a configuration may be useful in avoiding points of concentrated stress in, for example, the proximal self-expanding stent member 160 or struts 168. The proximal self-expanding stent member 160 may include at least one barb 165 and/or enlarged portion 180 on each strut 168, every other strut 168 or combinations thereof. One proximal self-expanding stent member 160 embodiment may have a repeated strut 168 pattern having a more proximally placed barb 165 on one strut 168, an adjacent neighbor strut 168 with a more distally placed barb 165, and a following adjacent strut 168 with a centrally placed enlarged portion 180, as shown in FIG. 3. Another enlarged portion embodiment 180 may have enlarged portions 180 on every strut 168, as shown in FIG. 5. Additionally, a proximal self-expanding stent member 160 embodiment may have a first self-expanding stent member 200 secured to a second self-expanding stent member 202 where the first self-expanding stent member 200 (or more proximal stent) may have alternating more distally placed barbs 165 along the struts 168 with more proximally placed barbs 165 along the struts 168, as shown in FIG. 9. Another proximal self-expanding stent member 160 embodiment may include one or more struts 168 having enlarged portions 180 generally centrally placed along the length of the struts 168, followed by alternating more distally placed barbs 165 with more proximally placed barbs 165 along the struts 168, as shown in FIG. 11.


For some embodiments, the first self-expanding member 200 of the proximal self-expanding stent member 160 may further include a plurality of barbs 165 having sharp tissue engaging tips that are configured to extend radially outward and distally in a deployed expanded state. This configuration may be useful in order to engage tissue of an inner luminal surface 132 of a patient's vasculature 130 and mechanically anchor the stent graft 150 to the vasculature 130, in addition to the anchoring function provided by the outward radial force of the proximal self-expanding stent member 160 against the inner luminal surface 132 of the patient's vasculature 130 when the stent graft 150 is in a deployed state. The second self-expanding member 202 of the proximal self-expanding stent member 160 may be secured to the proximal end 154 of the main body 152 of the stent graft 150 with one or more struts 168 and/or connector members 216 mechanically coupled to a proximal connector ring 164.


When loaded on the delivery catheter 100, the first and second self-expanding members 200, 202 of the proximal self-expanding stent member 160 may be radially constrained by releasable belts 104 and 106 which may be releasably held in a constraining configuration by a release member, such as a release wire 120. FIG. 2 shows an embodiment of the proximal self-expanding stent member 160 where the first self-expanding member 200 is being radially constrained by a first releasable belt 104 and the second self-expanding member 202 is being radially constrained by a second releasable belt 106. The first releasable belt 104 may be released by a first release wire 120 and the second releasable belt 106 may be deployed by the second release wire 120. The first and second self-expanding members 200 and 202 of the proximal anchor member may only be released after the outer sheath 102 has been retracted, as shown in FIG. 2, in order to expose the stent graft 150.


The strut 168 structure of the proximal self-expanding stent member 160 and/or distal self-expanding stent member 170 may be formed from a cylindrical metal tube structure which is carved or bore by laser or other cutting device. Thereafter, the cut tube may be heat set into two separate forms or states such as an expanded state and non-expanded/contracted state. FIG. 3 shows an example of a non-expanded state. The proximal self-expanding stent member 160 and/or distal self-expanding stent member 170 may include one or more barbs 165. A barb 165 may be any outwardly directed protuberance, typically terminating in a sharp point that is capable of at least partially penetrating a body passageway in which the stent graft 150 is deployed (typically the initial and medial layers of a blood vessel such as the abdominal aorta). The number of barbs 165, the length of each barb 165, each barb 165 angle, and the barb 165 orientation may vary from barb 165 to barb 165 within a single anchor member or between multiple anchor members (i.e., proximal self-expanding stent member 160 and/or distal self-expanding stent member 170) within a single stent graft 150. Although the various barbs 165 (and tuck pads 166, as will be discussed below) may be attached to or fixed on the struts 168, it may be preferred that they are integrally formed as part of the struts 168. When either the proximal self-expanding stent member 160 and/or distal self-expanding stent member 170 is deployed in the abdominal aorta, for example, typically in a location proximal to the aneurysm and any diseased tissue, barbs 165 may be designed to work in conjunction with the distally-oriented blood flow field. In this location, the barbs 165 may penetrate the tissue and prevent axial migration of the stent graft 150. As such, the barbs 165 may be oriented proximally with respect to the main body 152 section. However, the number, dimensions, configuration and orientation of barbs 165 may vary significantly, yet be within the scope of the present invention.


The staged deployment of the proximal self-expanding stent member 160 may also facilitate self-alignment of the stent graft 150. For instance, upon deployment of the proximal self-expanding stent member 160, the graft may be free to expand and enable distal fluid flow to flow through the stent graft 150 and create a “windsock” effect. That is, the distal fluid flow may apply a slight distal force generally upon the main body 152. This distal force may help to align at least the main body 152 and proximal self-expanding stent member 160 within the patient's vasculature 130, which may be particularly advantageous during deployment of the stent graft 150 within the angulated vasculature 130, for example.


In some embodiments of the stent graft 150, one or more struts 168 may include tuck pads 166. Additionally, the one or more struts 168 may have tuck pads 166 positioned such that the tuck pads 166 are generally aligned with a barb 165 extending from an adjacent strut 168, as shown in FIG. 11. As such, during preparation of the stent graft 150 into its reduced diameter delivery configuration (or non-expanded/contracted state), each barb 165 may be placed, for example, behind an adjacent strut 168 and/or tuck pad 166 in order to prevent the barbs 165 from radially extending and contacting the inside of a outer sheath 102 or delivery catheter 100 during delivery of the stent graft 150, as well as to prevent undesired contact of the barbs 165 with the inside luminal surface 132 of a patient's vasculature 130.


As illustrated in FIG. 3A, the struts 168 may have various circumferential dimensions and/or cross sectional areas 169. Enlarged portions 180 of a strut 168 may also include varying radial lengths generally along a longitudinal axis of the strut 168. Enlarged portions 180 may be aligned with barbs 165 and/or located at a generally unstable portion of a strut 168. In some stent graft 150 embodiments, when the stent (i.e., proximal self-expanding member 169) is in a compressed state, enlarged portions 180 may abut each other and may have one or more flat sides which prevent slippage by each other. Adjacent enlarged portions 180 that abut each other and circumferentially interfere with each other may be axially coextensive. In a radially compressed state, for example, the one or more enlarged portions 180 may be compressed to a radial diameter that is no greater than the remaining part of the stent 168.


In some embodiments, one or more struts 168 may have a tapered section 300. For example, one or more struts 168 may have a tapered section 300 in order to evenly distribute strain induced at least when the stent is in a constrained state. The strut 168 may taper from a first end portion of the strut 168 to a smaller transverse cross section towards a middle portion of the strut 168. As shown in FIG. 7B, a strut 168 embodiment may taper from a proximal end 400 portion towards a respective middle portion 402 and taper to a reduced transverse cross section from a distal end portion 404 towards a respective middle portion 402. The strut 168 may taper over half or approximately half of the length of the strut 168. In addition, the strut 168 may taper generally over the entire length of the strut 168, such as from the apex or crown of the anchor member or stent to the middle of the strut or to the first discontinuity feature (i.e., an enlarged portion 180, barb 165, tuck pad 166 and the like). The struts 168 may taper in at least one transverse dimension of the strut 168. Additionally, the struts 168 may taper along a circumferential direction about the longitudinal axis of the struts 168 may have a substantially constant thickness in a radial direction relative to the longitudinal axis of the stent, such as the proximal self-expanding stent member 160. The struts 168 may taper along a radial direction relative to the longitudinal axis of the anchor member or stent and the struts 168 may have a substantially constant thickness in a circumferential direction about the longitudinal axis of the anchor member or stent. The taper angle of a tapered section 300 of a strut 168 may be about 1 degree to about 3 degrees inclusive, about 1.5 degree to about 2.5 degrees inclusive, or about 1.75 degree to about 2.25 degrees inclusive. The strut 168 embodiments may taper continuously from each end portion to the respective middle portions, such as is shown by way of example in FIG. 9. The struts may include a stepped taper embodiment 302 which tapers in discrete steps rather than a smooth continuous taper from the distal and proximal end portions 404 and 400 of the respective middle portions 402 in either radial direction about the longitudinal axis. Such and embodiment is shown by way of example in FIG. 7C. The struts may also taper in a circumferential direction about the longitudinal axis, as shown in FIG. 8. The tapered sections 300 of the struts 168 may extend from proximal and distal end portions 400 and 404 of the struts 168 to respective strut structures (i.e., enlarged portions 180) disposed in, for example, the middle portion 402 of the respective strut 168, as shown by way of example in FIG. 8.



FIG. 5 illustrates a portion of a stent 500 embodiment which may function as a proximal self-expanding stent member 160. The stent 500 may include a plurality of struts 168 extending axially between the proximal end 402 and distal end 404 thereof. The stent 500 may be oriented in either direction, depending on the application. Both the proximal and distal ends 400 and 404 may have a plurality of crowns adjoining adjacent struts 168. The distal end 404 may have a plurality of connecting members 216 configured to connect the stent 500 to the main body 152 or other structure. The stent 500 embodiment may have various features (i.e., tuck pads 166, etc.) and structures and is not limited to the strut 168 features and structures illustrated herein. For example, the stent 500 may have a body defined by a lattice structure or a helical structure.


Optional taper (or tapers) may be incorporated into one or more of the struts 168 of the various stent 500 embodiments, as well as the various connector members 216. In general, incorporating one or more tapers into one or more of the struts 168 in one or more stents 500 may provide greater space in the tapered section 300 to accommodate alternative features such as barbs 165 and tuck pads 166. In addition, it may allow for a smaller deployment profile when the components are in a radially collapsed delivery configuration. When configuring the various stents 500 into this reduced diameter delivery profile (non-expanded/constrained state), the stents 500 may experience a large degree of bending strain that may be poorly distributed. Tapering certain stent 500 struts 168 in particular locations may help to distribute this strain more evenly throughout the stent 500 and/or strut 168 which may assist in preventing strain damage to the stent 500.



FIG. 5 illustrates a section of a stent 500, such as a proximal self-expanding stent member 160, in which the struts 168 taper from a proximal end 400 width to a minimum width about the middle portion 402 of the strut 168. An example transverse cross-section of the strut 168 taken along line 6AA-6AA, which is generally located in the proximal end 400 region of a strut 168, of FIG. 5 is shown in FIG. 6AA (which may or may not equal a width of strut 168 in the apex region or distal end 404). Another example transverse cross-section of the strut 168 taken along line 6A-6A, which is generally located in the minimum width, or near the middle portion 402 region of the strut 168, of FIG. 5 is shown in FIG. 6A. The optional taper, which may be expressed as the taper ratio, is the ratio of the maximum width (as shown, for example, in FIG. 6AA) to the minimum width (as shown in FIG. 6A) of a cross sectional area 169. The taper ratio may vary widely depending on, for example, the particular region of the strut 168 or connector member 216, the material used, and other factors. Taper ratios ranging from about 1 to about 10 or greater may be within the scope of the present invention. It may also be within the scope of the present invention for the struts 168 to have no taper (as shown by way of example in FIG. 7A).


FIGS. 6A-6EE, illustrate a variety of examples of varying transverse cross-sectional views taken at two different locations along a single strut 168. These figures illustrate examples of the different shapes and sizes a single cross sectional area 169 of a strut 168 may have. For instance, as described above, FIGS. 6A and 6AA show a pair of transverse cross section views of the strut 168 embodiment of FIG. 5 taken along the lines 6A-6A and 6AA-6AA which illustrates the rectangular shape of the cross sectional area 169 and the change in size of the cross sectional area 169 at two different locations along the strut 168. FIGS. 6B and 6BB illustrate another example embodiment of paired transverse cross section views of another strut 168 embodiment which illustrates the trapezoidal shape of the cross sectional area 169 and the change in size of the cross sectional area 169 at two different locations along the strut 168. FIGS. 6C and 6CC illustrate another example embodiment of paired transverse cross section views of another strut 168 embodiment which illustrates the inverse trapezoidal shape of the cross sectional area 169 and the change in size of the cross sectional area 169 at two different locations along the strut 168. FIGS. 6D and 6DD illustrate another example embodiment of paired transverse cross section views of another strut 168 embodiment which illustrates the elliptical shape of the cross sectional area 169 and the change in size of the cross sectional area 169 at two different locations along the strut 168. FIGS. 6E and 6EE illustrate another example embodiment of paired transverse cross section views of another strut 168 embodiment which illustrates the circular shape of the cross sectional area 169 and the change in size of the cross sectional area 169 at two different locations along the strut 168. The transverse cross sectional area 169 of one or more locations along a strut 168 are not limited to the sizes and shapes disclosed herein, and may be any number of sizes and shapes that may be incorporated in a strut 168 and/or stent 500 configuration.


A proximal self-expanding stent member 160 may have, for example, one or more struts 168 having a proximal end 400 portion and/or distal end 404 portion which may be made from NiTi and an effective maximum strut 168 width ranging from about 0.016 to about 0.032 inch; particularly from about 0.022 inch and about 0.028 inch, and a minimum strut 168 width between about 0.010 inch and about 0.026 inch; particularly from about 0.012 inch and about 0.022 inch. Additional tapered strut 168 embodiments are described and shown herein in the figures which may be used in other anchor members (such as the proximal and distal self-expanding stent members 160 and 170), stent 500 embodiments or connector members 216 described herein, and may be incorporated in any number of components and made from any number of materials. For example, tapering of the struts 168 in any configuration described herein may improve the strain distribution at least between the proximal end 400 portions and distal end 404 portions of the struts 168.


Various types of taper features or configurations may be implemented in any number of struts 168 for achieving a variety of strut 168 characteristics. For example, one or more struts 168 may include a taper having an offset radii and/or combinations of elliptical and/or circular apex radii in order to further cause the desired behavior during assembly into a reduced-diameter delivery configuration as well as effective delivery and performance in vivo. For example, the proximal end 400 portion, or apex, width may be the minimum width of the strut 168 which untapers towards the middle portion 402 of the strut 168, which may have the maximum width of the strut 168. The tapering from the proximal end 400 portion to the middle portion 402 of the strut 168 may be continuous, stepped in discrete steps 410 with straight untapered portions between each discrete step (as shown by way of example in FIGS. 7C and 8) or a combination thereof. Furthermore, untapering of the strut 168 may be in the radial and/or circumferential direction along the longitudinal length of the strut 168.


The strut 168 may include an enlarged portion 180 located in about the middle portion 402 of one or more of the struts 168, as shown by way of example in FIG. 5. By way of further example, one or more enlarged portions 180 may be located along every other strut 168 of the stent 500. The one or more enlarged portion 180 may be located along a strut 168 in various locations, such as near or at the proximal end 400 portion, middle portion 402, and/or distal end 404 portion of the strut 168. Additionally, the one or more enlarged portions 180 may be located at offset locations relative to enlarged portions 180 (or other features) along neighboring struts 168.


In some cases, the one or more enlarged longitudinal sections or enlarged portions 180 may have an enlarged transverse dimension that is about 1.5 times to about 3 times the nominal transverse dimension of the strut 168 in a direction of the enlargement. Additionally, the enlarged portions 180 may have an undulating configuration of the nominal strut 168. Furthermore, the enlarged portion 180 may have an oval enlargement of the nominal strut. Each strut 168 of the stent 500 having an enlarged portion 168 along the length of the strut 168 may have only one enlarged portion 180. Alternatively, each strut 168 of the stent 500 having an enlarged portion 180 along the length of the strut 168 may have more than one enlarged portion 180. The enlarged portions 180 are not limited to what are described and shown herein, and may be sized, featured, shaped, and proportioned in any number of ways that may assist in assembly or use of the stent 500. Additionally, any number of materials may be used and may vary between struts 168, anchor members (such as the proximal and distal self-expanding strut members 160 and 170), and/or stents 500.



FIG. 10A shows an example portion of a cylindrical stent embodiment 500 in a constrained configuration including struts 168 having generally coaxially aligned enlarged portion 180 embodiments having circular or oval features. FIG. 10B shows an example portion of a cylindrical stent embodiment 500 in a constrained configuration having struts 168 with generally coaxially aligned enlarged portion 180 embodiments having square or rectangular features. FIG. 10C shows a portion of a cylindrical stent embodiment 500 in a constrained configuration including struts 168 having undulating deflected portions 182 which may be configured to physically separate adjacent struts 168 in a circumferential direction.


One or more struts 168 of a stent embodiment 500 may have a stepped taper 302 feature generally along the length of the strut 168. For example, one or more struts 168 may have a stepped taper 302 from the proximal end 400 to the respective middle portion 402 of the strut 168 and/or a stepped taper 302 from the distal end 404 to the middle portion 402 of the strut 168, wherein the stepped taper 302 may be in either radial direction about the longitudinal axis of the strut 168, as shown by way of example in FIG. 7C, or the circumferential direction about the longitudinal axis, as shown by way of example in FIG. 8. The taper characteristics of a strut 168 may be continuous, stepped or any other shape configured to evenly distribute strain induced by the constraint of the constrained non-expanded stent 500.



FIG. 7A illustrates an example longitudinal section view taken along line 7A-7A of the strut 168 in FIG. 5 which shows a generally rectangular cross sectional area 169 having no radial tapering about the longitudinal axis. FIG. 7B illustrates another example of a longitudinal section view of a strut 168 which shows a generally tapered cross sectional area 169 due to radial tapering about the longitudinal axis of the strut 168. In FIG. 7B, the strut 168 tapers continuously from each end portion (the proximal and distal ends 400 and 404) to the middle portion 402 such that the middle portion 402 generally has the minimum strut 168 width in the radial direction. FIG. 7C shows another example strut 168 embodiment in longitudinal section including a radial stepped tapering 302 about the longitudinal axis of the strut 168. In FIG. 7C, the strut 168 generally tapers in steps continuously from each end portion (the proximal and distal ends 400 and 404) to the middle portion 402 such that the middle portion 402 generally has the minimum strut 168 width in the radial direction.



FIG. 8 shows a portion of an embodiment of a stent 500 including struts 168 having a circumferential stepped taper 302 configuration about the longitudinal axis of the strut 168. The middle portion 402 of each strut 168 may also include an enlarged portion 180 extending, for example, in a circumferential direction. Portions of the stepped taper 302 of a strut 168 that may be directly adjacent an enlarged portion 180 may have the minimum strut 168 width in the circumferential direction. However, any number of combinations of tapering in any direction may be used.



FIG. 9 shows a stent embodiment 500 where the proximal self-expanding stent member 160 has a first self-expanding member 200 secured to a second self-expanding member 202 where the first self-expanding member 200 has alternating more proximally placed barbs 165 along the struts 168 with more distally placed barbs 165 along the struts 168. In addition, the stent embodiment 500 may have a continuous taper in the second self-expanding member 202, which is the portion of the proximal self-expanding stent member 160 adjacent the main body 152. Each strut 168 on the first self-expanding member 168 may have a barb 165 in a different location relative to a neighboring strut 168. The barbs 165 may be formed integrally with the struts 168, but may otherwise be manufactured, for example, as a separate component attached to the struts 168. In general, the struts 168 and the barbs 165 of the stent embodiments 500 and anchor members may be self-expanding, that is, upon release of a constraining force, the struts 168 may move radially apart and the barbs 165 may extend radially outward. Other configurations, such as balloon expansion, are also contemplated within the present invention.


In addition, stent embodiments 500 may include struts 168 including tuck pads 166, which may be positioned along a strut 168 such that the tuck pads 166 are axially aligned with a barb 165 positioned on a neighboring strut 168. Similar to the barbs 165 and enlarged portions 180, the number, dimensions, configurations and orientations of the tuck pads 166 may vary between struts 168, stent embodiments 500 and anchor members (such as the proximal and distal self-expanding stent members 160 and 170 described herein).


During preparation of a stent graft embodiment 150 (and therefore one or more proximal self-expanding stent members 160) into a reduced diameter delivery configuration, one or more barbs 165 may be placed behind a corresponding strut 168 and/or tuck pad 166, if present, in order to prevent the barbs 165 from contacting the inside of a outer sheath 102 or delivery catheter 100 during delivery of the stent graft 150 and from undesired contact with the interior luminal surface 132 of the patient's vasculature 130. As described in U.S. patent application Ser. No. 09/917,371 to Chobotov et al., now U.S. Pat. No. 6,761,733, and which is incorporated by reference herein in its entirety, a release belt may be disposed in one or more grooves (not shown) disposed on one or more struts 168 which may assist in retaining the proximal self-expanding stent member 160 in the reduced diameter delivery configuration.


For example, upon deployment of stent graft 150, and more particularly the proximal self-expanding stent member 160, (typically accomplished, at least in part, by release of one or more belts, such as the proximal releasable belts 104 and 106), the radial expansion of the proximal self-expanding stent member 160 results in a displacement of struts 168 so that the distance between them increases. Eventually, the displacement between the struts 168 become large enough to enable the barbs 165 to be released from behind the adjacent strut 168 and/or tuck pad 166 and engage the interior luminal surface 132 of the patient's vasculature 130. In general, the barbs 165 may release into a position suitable for engaging the interior luminal surface 132 of a patient's vasculature with a time constant that is generally an order of magnitude lower than the time constant associated with the radial expansion of the stent 500 embodiment or anchor member (such as the proximal self-expanding stent member 160). In other words, during the stent 500 or anchor member deployment process, the one or more barbs 165 may complete their deployment before the stent 500 or anchor member is fully expanded so that the barbs 165 may engage the interior luminal surface 132 of the vasculature 130 with maximum effectiveness.


Referring again to FIG. 9, the proximal self-expanding stent member 160 may include struts 168, any one of which may further comprise one or more barbs 165. In addition, optional tuck pads 166 may be positioned along a strut 168 such that the tuck pad 166 is coaxially aligned with a barb 165 on a neighboring strut 168 in order to shield the neighboring barb 165 at least when the stent graft 150 is in its reduced diameter delivery configuration. Struts 168 and/or tuck pads 166 may also include a tuck slot 167 which may assist in retaining a barb 165 while the stent graft 150 (and consequently the proximal self-expanding stent member 160) is in its reduced diameter delivery configuration. Upon deployment of a stent graft 150 embodiment, the one or more barbs 165 may be released from respective tuck slots 167 and thereafter placed in an operational or deployed configuration for engaging a patient's vasculature 130.



FIG. 11 shows a portion of a cylindrical stent embodiment 500 in a generally constrained and flattened configuration having struts 168 with a coaxial enlarged portion 180 embodiments and undulating deflected portions 182. The undulating deflected portions 182 may have barbs 165 positioned at offset proximal and distal locations along neighboring struts 168 which may aid in efficiently compacting the struts 168 and barbs 165 in a constrained configuration for delivery into a patient's body. By alternating axial location of the barbs 165 and/or enlarged portions 180 along neighboring struts 168, the stent 500 may be optimally compressed. The undulating deflected portions 182 of a strut 168 may enable multiple lateral contact points within the stent 500. Such multiple contact points may aid in restraining or compacting the stent 500 in a constrained/non-expanded state. In some embodiments, one or more struts 168 may have enlarged longitudinal sections or enlarged portions 180 that may be disposed in a substantially longitudinal orientation between the proximal end and distal end of the stent 500 when the stent 500 is in the constrained state. Additionally, the one or more struts 168 may be disposed in an undulating pattern. FIG. 12 shows a transverse cross section view of the stent 500 portion of FIG. 11 taken along lines 12-12 of FIG. 11. FIG. 12 illustrates an example of the varying circumferential cross sectional areas 169 of the struts 168 taken along a transverse cross section of the strut 500.


As discussed above, some embodiments of a modular endovascular stent graft assembly may include a bifurcated graft member 600 with a proximal stent or anchor member 602 secured thereto. In some cases, the main body member 604 may be formed from a supple graft material, such as ePTFE, having a main fluid flow lumen 606 therein. FIG. 13 illustrates such an embodiment. Referring to this figure, the main graft portion 604 may include an ipsilateral leg 608 with an ipsilateral fluid flow lumen 610 in communication with the main fluid flow lumen 606, a contralateral leg 612 with a contralateral fluid flow lumen 614 in communication with the main fluid flow lumen 606 and a network of inflatable channels 616 disposed on the main graft member 604. For some embodiments, the main graft or main body member 604 may have an axial length of about 5 cm to about 10 cm, more specifically, about 6 cm to about 8 cm in order to span an aneurysm 622 of a patient's aorta 618 without engaging the patient's iliac arteries 620 directly with the legs 608 and 612 of the main graft member 604 (see FIG. 14).


The inflatable channels of the network of inflatable channels 616 may be disposed on any portion of the main graft or main body member 604 including the ipsilateral and contralateral legs 608 and 612. The network of inflatable channels 616 may be configured to accept a hardenable fill material to provide structural rigidity to the main body 604 member when the network of inflatable channels 616 are in an inflated state and the inflation material has been cured or hardened. Radiopaque inflation material may be used to facilitate monitoring of the fill process and subsequent engagement of graft extensions. The network of inflatable channels 616 may also include at least one inflatable cuff 624 disposed on a proximal portion of the main body member which may be configured to seal against an inside surface of a patient's vessel, such as the aorta.


The proximal anchor member 626, which may have a substantially tubular or cylindrical configuration, may be disposed at a proximal end 628 of the main body member 604 and secured to the main body member 604 in any suitable manner including stitching, adhesive bonding, welding, and the like. The proximal anchor member 626 may also be secured to the main body 604 with a resilient connector ring (not shown) which may be embedded in a proximal end or portion 628 the main body 604. The proximal anchor member 626 may have a self-expanding proximal stent portion 630 secured to a self-expanding distal stent portion 632. Each of these stent portions 630 and 632 may include an undulating elongate stent element that may be disposed in a somewhat serpentine or sinusoidal configuration, as shown above with regard to stent members 160 and 170. Each of the stent portions 630 and 632 of the proximal anchor member 626 of the stent graft 600 in FIG. 13 may share any or all of the features, dimensions or materials of stent members 160 and 170 discussed above. For example, the proximal and distal stent portions 630 and 632 of the proximal anchor member 626 may include tapered struts 634 that extend between crown portions 636 of each respective stent portion 630 or 632. Such tapered struts 634 may have any or all of the features, dimensions, and materials of the struts discussed above and include a tapered strut configuration that allows for the strain imposed on the strut structure to be evenly distributed through the structure of the stent portion or portions 630 and 632.


In some cases, the proximal stent portion 630 may be secured to the distal stent portion 632 with one or more struts or strut segments 638 disposed between the respective proximal and distal stent sections 630 and 632. Some embodiments of such interconnecting struts 638 may have a cross sectional area that is substantially the same as or greater than a cross sectional area of proximal stent portions 630 or distal stent portions 632 adjacent the strut 638. Such configurations may be useful in avoiding points of concentrated stress in the proximal anchor member 602 or struts 638 which couple components thereof. For some embodiments, the proximal stent portion 630 of the proximal anchor member 602 may further include a plurality of barbs 640 having sharp tissue engaging tips 642 that are configured to extend in a radial outward direction in a deployed expanded state (see FIG. 15). For some embodiments, each stent portion 630 and 632 of the proximal anchor member 602 may include about 5 crowns 636 to about 8 crowns 636 at either end of the respective section 630 or 632 and may be made from a superelastic alloy such as superelastic NiTi alloy.


At least one tubular ipsilateral graft extension 644 having a fluid flow lumen 646 disposed therein may be deployed with the fluid flow lumen 646 of the graft extension 644 sealed to and in fluid communication with the fluid flow lumen 610 of the ipsilateral leg 608 of the main body member 604. In addition, at least one tubular contralateral graft extension 648 having a fluid flow lumen 650 disposed therein may be deployed with the fluid flow lumen 650 of the graft extension 648 sealed to and in fluid communication with the fluid flow lumen 614 of the contralateral leg 612 of the main body member 604. For some embodiments, the graft extensions 644 and 648 may include an interposed self-expanding stent 652 disposed between at least one outer layer and at least one inner layer of supple layers of graft material. The interposed stent disposed between the outer layer and inner layer of graft material may be formed from an elongate resilient element helically wound with a plurality of longitudinally spaced turns into an open tubular configuration. For some embodiments, the interposed stent 652 may include a superelastic alloy such as superelastic NiTi alloy. In addition, the graft material of each graft extension 644 and 648 may further include at least one axial zone of low permeability for some embodiments.


For some embodiments, an outside surface of the graft extension 648 may be sealed to an inside surface of the contralateral leg 612 of the main body 604 when the graft extension 648 is in a deployed state. For some embodiments, the axial length of the ipsilateral and contralateral legs 608 and 612 may be sufficient to provide adequate surface area contact with outer surfaces of graft extensions 644 and 648 to provide sufficient friction to hold the graft extensions 644 and 648 in place. For some embodiments, the ipsilateral and contralateral legs 608 and 612 may have an axial length of at least about 2 cm. For some embodiments, the ipsilateral and contralateral legs 608 and 612 may have an axial length of about 2 cm to about 6 cm, more specifically, about 3 cm to about 5 cm.


For the bifurcated stent graft embodiment 600 discussed above or any other suitable stent graft embodiment discussed herein that includes a proximal self-expanding anchor member 602, it may be desirable in some cases to constrain each of the proximal and distal stent portions 630 and 632 separately so that each of the proximal and distal stent portions 630 and 632 of the proximal anchor member 602 can be deployed from a radially constrained state independent of each other. FIG. 14 shows the stent graft 600 having an 8 crown distal stent portion 632 with marker elements 654 disposed at a distal end 656 of the distal stent portion 632. Other than this variation in the proximal anchor configuration, the stent graft of FIG. 14 may have the same features, dimensions and materials as those of the stent graft 600 shown in FIG. 13.


The stent graft 600 of FIG. 14 is shown in a partially deployed state within an abdominal aorta 618 of a patient with the proximal end 628 of the main body 604 disposed just below and in a non-interfering relationship with the renal arteries 658 which extend from and are in communication with the patient's aorta. The main body 604 of the stent graft 600 also extends substantially across the aneurysm 622 of the aorta 618, however, this relationship may vary depending on the size of the graft 600 used and the morphology of the aneurysm 632. The proximal stent portion 630 of the proximal anchor member 602 is still constrained by a releasable member or belt 660 such that it has an outer dimension or profile suitable for delivery within a catheter assembly within the patient's vasculature. The distal stent portion 632, however, has been released from a constrained state and has expanded radially such that the distal end 656 of the distal stent portion 632 has expanded outwardly in approximation to the inner surface 662 of the patient's aorta 618.


In such cases, a proximal anchor member 602 configured to allow the distal end 656 of the distal stent portion 632 to so expand may be desirable. For example, the markers 654 disposed at the distal end 656 of the distal stent portion 632 are substantially open and are close to or in contact with the inner wall 662 of the patient's aorta 68 providing good visualization of the position of the partially deployed stent graft 600 under fluoroscopy. This configuration may allow the physician deploying the stent graft 600 to visualize the position of the stent graft 600 and accurately predict what the final position of the stent graft 600 will be after complete deployment. However, such a configuration may also allow the physician to adjust the position of the stent graft 600 prior to full deployment of the proximal anchor member 602. In other words, the stent graft 600 and markers 654 at the distal end 656 of the distal stent portion 632 are sufficiently expanded so that the physician can easily see how the stent graft 600 will be positioned when fully deployed before the physician has deployed the proximal stent portion 630 in which case the barbs 640 or other tissue engaging members of the proximal stent portion 630 engage the tissue of the inner wall 662 of the patient's aorta 618.


We have found that in some instances, in order to configure an anchor member 602 such that the distal end 656 of the distal stent portion 632 opens or radially expands sufficiently upon release from a constrained state, that certain design parameters or criteria may be desirable. In particular, such a stent portion 632 may benefit from a configuration that produces a good distal opening force or maximum opening force in an outward radial direction. In order to produce a generous opening force in an outward radial direction, the section of the struts 634 and crowns 636 of the proximal and distal stent portions 630 and 632 may be increased, however, it may also be desirable to adjust the tapering profile of the struts 634 in order to maintain a substantially even distribution of strain throughout the structure of the stent portions 630 and 632. For some embodiments, a useful outward opening force may include about 0.5 to about 0.75 lbf of force for a stent embodiment that is about 14 mm to about 16 mm in outer diameter in a relaxed unconstrained state.


In cases such as the stent graft embodiment 600 of FIG. 13 wherein the proximal anchor member 602 includes both a proximal stent portion 630 and a distal stent portion 632, it may be useful to vary the axial lengths of the respective proximal and distal portions 630 and 632 of the anchor member 602. Such an unsymmetric arrangement may be beneficial in cases such as the partial deployment sequence step shown in FIG. 14 wherein the constraint on the distal stent portion 632 has been released so as to allow radial expansion of the distal portion 632 but the proximal stent portion 630 remains constrained.



FIG. 15 illustrates an embodiment of the proximal anchor member 602 having a 5 crown proximal stent portion 630 and a five crown distal stent portion 632. An attachment ring 664 is secured to each crown 636 of the distal end 656 of the distal stent portion 632. Such attachment rings 664 may be secured to the proximal end 628 of main body 604 by stitching the ring 664 to the flexible material of the main body portion 604 with suture or any other suitable material. Such attachment rings 664 may also be secured to the main body 604 by any other suitable method including any of the attachment methods and devices discussed above. A cutaway portion 668 of the proximal anchor member 602 is shown at the ends of arrows 665 to illustrate an element of the proximal anchor member 602 for further discussion. The cutaway portion 668 includes a distal crown 670 and respective stent struts 634 attached thereto from the distal stent portion 632 and a proximal crown 672 and respective stent struts 634 attached thereto from the proximal stent portion 630. The proximal end of the distal stent portion 632 is secured to the distal end 676 of the proximal stent portion 630 by strut segments 638.



FIG. 16 illustrates the cutaway portion 668 of the proximal anchor member 602 of FIG. 15 with an adjacent arrow 678 that indicates the axial length of the proximal stent portion 630 and an arrow 680 that indicates the axial length of the proximal stent portion 630 together with the distal stent portion 632 or, in other words, the axial length of the proximal anchor member 602 as a whole. For some embodiments, it has been determined that one or more of the design parameters discussed above may be optimized by use of a proximal anchor member 602 having a proximal stent portion 630 and a distal stent portion 632 wherein the axial length of the proximal anchor member 602 as a whole (Lstent) divided by the axial length of the proximal stent portion 630 (Lproximal) is a ratio of about 1.75 to about 2.5, more specifically, about 1.75 to about 2.1, and even more specifically, about 1.75 to about 1.9. Such a configuration may be useful for a multi-element stent or proximal anchor member 602 in order to maximize opening force and minimize peak strain within the proximal anchor member 602.


It has also been discovered that for such proximal anchor member embodiments 600 as shown in FIG. 16 including unsymmetric axial lengths of the proximal stent portion 630 and distal stent portion 632, that it may also be useful to include unsymmetric taper lengths. FIG. 17 illustrates the cutaway portion 668 of the proximal anchor member 602 of FIG. 15 with an arrow 682 that indicates the axial length of the tapered portion 684 of the strut 634 that tapers from the proximal end 674 of the distal stent portion 632 towards the distal end 656 of the distal stent portion 632. Such a tapered portion 684 extends from the crown 686 of the distal stent portion 632 at a proximal end thereof to an axial position of minimum strut cross section 688 between the proximal crown 686 and distal crown 670 of the distal stent portion 632. Distal of the position of minimum section 688 on the strut 634, the strut 634 may begin to flare and increase in section towards the distal crown 670. Thus, the point of minimum section 688 on the strut 634 represents the endpoint of the tapered portions 684 of the strut 634 which begin at each respective crown 670 and 686 of the distal stent portion 632. For some stent embodiments 602, a strut taper configuration wherein the axial length of the proximal anchor member as a whole 602 or Lstent divided by the axial length of the tapered strut 634 from the crown 686 of the distal stent portion 632 at a proximal end 674 thereof to an axial position of minimum strut cross section 688 between the proximal crown 686 and distal crown 670 of the distal stent portion 632 (Ltaper) is about 3.0 to about 4.5, may be particularly useful in order to maximize opening force and reduce or minimize peak strains within the structure of the proximal anchor member 602. It should also be noted that such unsymmetric taper lengths may also be used for multi-element stents or proximal anchor members 602 having stent portions 630 and 632 of equal axial length.


Another design parameter that may be useful when maximizing opening force and minimizing peak strain within a proximal anchor member 602 is selection of the inner crown radius of the crowns 636 at each end of the respective proximal and distal stent portions 630 and 632. FIGS. 18 and 19 illustrate an inner crown radius R of a distal crown 670 of the distal stent portion 632 of the proximal anchor member 602. For some embodiments, it may be useful to have an inner crown radius R of about 0.001 inches to about 0.005 inches, more specifically, about 0.001 inches to about 0.004 inches. It should be noted that such inner crown radii dimensions R may also be used for single element stents or proximal anchor members 160 and 170, particularly in embodiments where it is desirable to maximize opening force and minimize peak strains within the proximal anchor member.


For some particular stent graft embodiments 600 having a bifurcated main body 604 and a multi-element proximal anchor member 602, the proximal anchor member 602 may be configured to open to a maximum diameter of about 29 mm to about 31 mm, more specifically, about 30 mm, the proximal anchor member may have an overall axial length Lstent of about 35 mm to about 37 mm, more specifically, about 36 mm, an opening force of about 0.5 lbf to about 0.7 lbf, more specifically, about 0.6 lbf, and a ratio of the axial length 680 of the anchor member 602 Lstent divided by the axial length 678 of the proximal stent portion 630 Lproximal of about 2.0 to about 2.2, more specifically, about 2.1. Such an embodiment 600 may also have a distal stent portion 632 with a strut taper configuration wherein the length 680 of the proximal anchor member 602 as a whole Lstent divided by the length 682 of the tapered strut 639 from the crown 686 of the distal stent portion 632 at a proximal end thereof to an axial position of minimum strut cross section 688 between the proximal crown 686 and distal crown 670 of the distal stent portion 632 (Ltaper) is about 3.0 to about 3.2, more specifically, about 3.1. Many other embodiments following the design parameters discussed above may also be used in order to maximize opening force and minimize peak strain within the proximal anchor member 602. As discussed above, these design parameters may also be used singly or in any combination in order to achieve the desired results in either single element stents 160 and 170 or multi-element stents 600 having a proximal stent portion 630, distal stent portion 632 or any other number of stent portions.


While preferred embodiments of the invention have been shown and described herein, it will be understood that such embodiments are provided by way of example only. Numerous variations, changes and substitutions will occur to those skilled in the art without departing from the spirit of the invention. Accordingly, it is intended that the appended claims cover all such variations as fall within the spirit and scope of the invention.


The number of barbs, enlarged portions or tapers per strut, the length of each barb, enlarged portions or tapers, each of the barb angles or tapered angle described above, and the barb, enlarged portion or tapered orientation may vary from barb to barb, enlarged portion to enlarged portion, strut to strut within a single stent or between multiple stents within a single graft.


The entirety of each patent, patent application, publication and document referenced herein hereby is incorporated by reference. Citation of the above patents, patent applications, publications and documents is not an admission that any of the foregoing is pertinent prior art, nor does it constitute any admission as to the contents or date of these publications or documents.


Modifications may be made to the foregoing without departing from the basic aspects of the invention. Although embodiments of the invention have been described in substantial detail with reference to one or more specific embodiments, those of ordinary skill in the art will recognize that changes may be made to the embodiments specifically disclosed in this application, yet these modifications and improvements are within the scope and spirit of the invention.


Embodiments illustratively described herein suitably may be practiced in the absence of any element(s) not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising,” “consisting essentially of,” and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation and use of such terms and expressions do not exclude any equivalents of the features shown and described or portions thereof and various modifications are possible within the scope of the invention claimed. The term “a” or “an” can refer to one of or a plurality of the elements it modifies (e.g., “a reagent” can mean one or more reagents) unless it is contextually clear either one of the elements or more than one of the elements is described. Thus, it should be understood that although embodiments have been specifically disclosed by representative embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and such modifications and variations are considered within the scope of this invention.


Certain embodiments of the invention are set forth in the claim(s) that follow(s).

Claims
  • 1. An endovascular stent graft, comprising: a main body portion including at least one tubular portion made from at least one layer of flexible material; anda self-expanding proximal anchor member which includes: a constrained state,a relaxed expanded state,a proximal stent portion,a distal stent portion with a proximal end of the distal stent portion secured to a distal end of the proximal stent portion and a distal end of the distal stent portion secured to a proximal end of the main body portion, and wherein the axial length of the self-expanding anchor member as a whole divided by the axial length of the proximal stent portion is about 1.75 to about 2.5, and wherein an axial length of the self-expanding proximal anchor member as a whole divided by an axial length of a tapered strut from a proximal crown of the distal stent portion at a proximal end thereof to an axial position of minimum strut cross section between the proximal crown and a distal crown of the distal stent portion is a ratio of about 3.0 to about 4.5.
  • 2. A self-expanding anchor member, comprising: a constrained state,a relaxed expanded state,a proximal stent portion,a distal stent portion with a proximal end of the distal stent portion secured to a distal end of the proximal stent portion, and wherein an axial length of the self-expanding anchor member as a whole divided by the axial length of the proximal stent portion is about 1.75 to about 2.5 and wherein an axial length of the self-expanding anchor member as a whole divided by an axial length of a tapered strut from a proximal crown of the distal stent portion at a proximal end thereof to an axial position of minimum strut cross section between the proximal crown and a distal crown of the distal stent portion is a ratio of about 3.0 to about 4.5.
RELATED APPLICATIONS

This application claims priority under 35 U.S.C. 119(e) from U.S. Provisional Patent Application No. 61/620,362, filed Apr. 4, 2012, by D. Parsons et al., titled Durable Stent Graft with Tapered Struts and Stable Delivery Methods and Devices, which is incorporated by reference herein in its entirety.

US Referenced Citations (1140)
Number Name Date Kind
3076737 Roberts Feb 1963 A
3540431 Uddin Nov 1970 A
3631854 Fryer et al. Jan 1972 A
3657744 Ersek Apr 1972 A
3669586 Kramer Jun 1972 A
3814137 Martinez Jun 1974 A
3818511 Goldberg et al. Jun 1974 A
3902198 Rathjen Sep 1975 A
3991767 Miller et al. Nov 1976 A
4096227 Gore Jun 1978 A
4110392 Yamasaki Aug 1978 A
4140126 Choudhury Feb 1979 A
4183102 Guiset Jan 1980 A
4187390 Gore Feb 1980 A
4208745 Okita Jun 1980 A
4214587 Sakura, Jr. Jul 1980 A
4229838 Mano Oct 1980 A
4248924 Okita Feb 1981 A
4330126 Rumble May 1982 A
4385093 Hubis May 1983 A
4416028 Eriksson et al. Nov 1983 A
4434797 Silander Mar 1984 A
4459252 MacGregor Jul 1984 A
4474630 Planck et al. Oct 1984 A
4478665 Hubis Oct 1984 A
4482516 Bowman et al. Nov 1984 A
4497074 Rey et al. Feb 1985 A
4503569 Dotter Mar 1985 A
4512338 Balko et al. Apr 1985 A
4550447 Seiler, Jr. et al. Nov 1985 A
4552707 How Nov 1985 A
4562596 Kornberg Jan 1986 A
4577631 Kreamer Mar 1986 A
4580568 Gianturco Apr 1986 A
4592754 Gupte et al. Jun 1986 A
4617932 Kornberg Oct 1986 A
4647416 Seiler, Jr. et al. Mar 1987 A
4655769 Zachariades Apr 1987 A
4655771 Wallsten Apr 1987 A
4665906 Jervis May 1987 A
4705517 DiPisa, Jr. Nov 1987 A
4731073 Robinson Mar 1988 A
4733665 Palmaz Mar 1988 A
4739762 Palmaz Apr 1988 A
4740207 Kreamer Apr 1988 A
4743480 Campbell et al. May 1988 A
4760102 Moriyama et al. Jul 1988 A
4776337 Palmaz Oct 1988 A
4787899 Lazarus Nov 1988 A
4816028 Kapadia et al. Mar 1989 A
4830003 Wolff et al. May 1989 A
4856516 Hillstead Aug 1989 A
4871365 Dumican Oct 1989 A
4877661 House et al. Oct 1989 A
4902423 Bacino Feb 1990 A
4932938 Goldberg et al. Jun 1990 A
4941870 Okada et al. Jul 1990 A
4955899 Della et al. Sep 1990 A
4957669 Primm Sep 1990 A
4985296 Mortimer, Jr. Jan 1991 A
4994071 MacGregor Feb 1991 A
4994077 Dobben Feb 1991 A
5019090 Pinchuk May 1991 A
5041126 Gianturco Aug 1991 A
5052998 Zimmon Oct 1991 A
5059211 Stack et al. Oct 1991 A
5064435 Porter Nov 1991 A
5098625 Huang et al. Mar 1992 A
5100422 Berguer et al. Mar 1992 A
5104399 Lazarus Apr 1992 A
5104400 Berguer et al. Apr 1992 A
5104404 Wolff Apr 1992 A
5108424 Hoffman, Jr. et al. Apr 1992 A
5110527 Harada et al. May 1992 A
5116365 Hillstead May 1992 A
5122154 Rhodes Jun 1992 A
5123917 Lee Jun 1992 A
5133732 Wiktor Jul 1992 A
5135536 Hillstead Aug 1992 A
5139480 Hickle et al. Aug 1992 A
5150304 Berchem et al. Sep 1992 A
5151105 Kwan-Gett Sep 1992 A
5152782 Kowligi et al. Oct 1992 A
5156620 Pigott Oct 1992 A
5158548 Lau et al. Oct 1992 A
5163955 Love Nov 1992 A
5167614 Tessmann Dec 1992 A
5171262 MacGregor Dec 1992 A
5192310 Herweck et al. Mar 1993 A
5195984 Schatz Mar 1993 A
5197976 Herweck et al. Mar 1993 A
5197978 Hess Mar 1993 A
5201757 Heyn et al. Apr 1993 A
5202352 Okada et al. Apr 1993 A
5207695 Trout, III May 1993 A
5217483 Tower Jun 1993 A
5219355 Parodi et al. Jun 1993 A
5226913 Pinchuk Jul 1993 A
5234456 Silvestini Aug 1993 A
5250059 Andreas et al. Oct 1993 A
5275622 Lazarus et al. Jan 1994 A
5282823 Schwartz et al. Feb 1994 A
5282824 Gianturco Feb 1994 A
5282847 Trescony et al. Feb 1994 A
5290305 Inoue Mar 1994 A
5292331 Boneau Mar 1994 A
5304200 Spaulding Apr 1994 A
5314472 Fontaine May 1994 A
5316023 Palmaz et al. May 1994 A
5320100 Herweck et al. Jun 1994 A
5321109 Bosse et al. Jun 1994 A
5330528 Lazim Jul 1994 A
5334164 Guy et al. Aug 1994 A
5334201 Cowan Aug 1994 A
5344426 Lau et al. Sep 1994 A
5344444 Glastra Sep 1994 A
5344451 Dayton Sep 1994 A
5350398 Pavcnik Sep 1994 A
5354310 Garnic et al. Oct 1994 A
5354329 Whalen Oct 1994 A
5360443 Barone et al. Nov 1994 A
5365996 Crook Nov 1994 A
5366504 Andersen et al. Nov 1994 A
5370682 Schmitt Dec 1994 A
5370691 Samson Dec 1994 A
5374473 Knox et al. Dec 1994 A
5382261 Palmaz Jan 1995 A
5383892 Cardon et al. Jan 1995 A
5383928 Scott et al. Jan 1995 A
5387235 Chuter et al. Feb 1995 A
5389106 Tower et al. Feb 1995 A
5391147 Imran et al. Feb 1995 A
5397345 Lazarus Mar 1995 A
5405377 Cragg Apr 1995 A
5405378 Strecker Apr 1995 A
5405379 Lane Apr 1995 A
5411550 Herweck et al. May 1995 A
5415634 Glynn et al. May 1995 A
5423851 Samuels Jun 1995 A
5433909 Martakos et al. Jul 1995 A
5437900 Kuzowski Aug 1995 A
5441515 Khosravi et al. Aug 1995 A
5443458 Eury Aug 1995 A
5443498 Fountaine Aug 1995 A
5445646 Euteneuer et al. Aug 1995 A
5447152 Kohsai et al. Sep 1995 A
5449373 Pinchasik et al. Sep 1995 A
5456713 Chuter Oct 1995 A
5464419 Glastra Nov 1995 A
5464449 Ryan et al. Nov 1995 A
5466509 Kowllgl et al. Nov 1995 A
5474824 Martakos et al. Dec 1995 A
5476506 Lunn Dec 1995 A
5476589 Bacino Dec 1995 A
5478330 Imran et al. Dec 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5489295 Piplani et al. Feb 1996 A
5505887 Zdrahala et al. Apr 1996 A
5507769 Marin et al. Apr 1996 A
5507770 Turk Apr 1996 A
5512360 King Apr 1996 A
5514154 Lau et al. May 1996 A
5522880 Barone et al. Jun 1996 A
5522881 Lentz Jun 1996 A
5522883 Slater et al. Jun 1996 A
5524633 Heaven et al. Jun 1996 A
5527353 Schmitt Jun 1996 A
5527355 Ahn Jun 1996 A
5529653 Glastra Jun 1996 A
5529820 Nomi et al. Jun 1996 A
5534024 Rogers et al. Jul 1996 A
5536274 Neuss Jul 1996 A
5545135 Iacob et al. Aug 1996 A
5549662 Fordenbacher Aug 1996 A
5549663 Cottone, Jr. Aug 1996 A
5552100 Shannon et al. Sep 1996 A
5554180 Turk Sep 1996 A
5554181 Das Sep 1996 A
5554183 Nazari Sep 1996 A
5554185 Block et al. Sep 1996 A
5556414 Turi Sep 1996 A
5556426 Popadiuk et al. Sep 1996 A
5560986 Mortimer, Jr. Oct 1996 A
5562697 Christiansen Oct 1996 A
5562724 Vorwerk et al. Oct 1996 A
5562726 Chuter Oct 1996 A
5562727 Turk et al. Oct 1996 A
5562728 Lazarus et al. Oct 1996 A
5569295 Lam Oct 1996 A
5571171 Barone et al. Nov 1996 A
5571172 Chin Nov 1996 A
5571173 Parodi Nov 1996 A
5575817 Martin Nov 1996 A
5575818 Pinchuk Nov 1996 A
5578071 Parodi Nov 1996 A
5578072 Barone et al. Nov 1996 A
5588964 Imran et al. Dec 1996 A
5591195 Taheri et al. Jan 1997 A
5591197 Orth et al. Jan 1997 A
5591229 Parodi Jan 1997 A
5597378 Jervis Jan 1997 A
5603721 Lau et al. Feb 1997 A
5607478 Lentz et al. Mar 1997 A
5609624 Kalis Mar 1997 A
5609625 Piplani et al. Mar 1997 A
5609627 Goicoechea et al. Mar 1997 A
5609628 Keranen Mar 1997 A
5609629 Fearnot Mar 1997 A
5612885 Love Mar 1997 A
5618301 Hauenstein et al. Apr 1997 A
5620763 House et al. Apr 1997 A
5626599 Bourne et al. May 1997 A
5628783 Quiachon et al. May 1997 A
5628786 Banas et al. May 1997 A
5628788 Pinchuk May 1997 A
5630829 Lauterjung May 1997 A
5632772 Alcime et al. May 1997 A
5632840 Campbell May 1997 A
5639278 Dereume et al. Jun 1997 A
5641373 Shannon et al. Jun 1997 A
5645915 Kranzler et al. Jul 1997 A
5649978 Samson Jul 1997 A
5653745 Trescony et al. Aug 1997 A
5653746 Schmitt Aug 1997 A
5656029 Imran et al. Aug 1997 A
5662675 Stockert et al. Sep 1997 A
5662700 Lazarus Sep 1997 A
5665115 Cragg Sep 1997 A
5665117 Rhodes Sep 1997 A
5667523 Bynon et al. Sep 1997 A
5669936 Lazarus Sep 1997 A
5676671 Inoue Oct 1997 A
5676696 Marcade Oct 1997 A
5676697 McDonald Oct 1997 A
5681346 Orth et al. Oct 1997 A
5683449 Marcade Nov 1997 A
5683451 Lenker et al. Nov 1997 A
5683453 Palmaz Nov 1997 A
5690644 Yurek et al. Nov 1997 A
5693083 Baker et al. Dec 1997 A
5693084 Chuter Dec 1997 A
5693087 Parodi Dec 1997 A
5693088 Lazarus Dec 1997 A
5697968 Rogers et al. Dec 1997 A
5697971 Fischell et al. Dec 1997 A
5700285 Myers et al. Dec 1997 A
5707378 Ahn et al. Jan 1998 A
5707388 Lauterjung Jan 1998 A
5708044 Branca Jan 1998 A
5709701 Parodi Jan 1998 A
5709703 Lukie et al. Jan 1998 A
5712315 Dolan Jan 1998 A
5713917 Leonhardt et al. Feb 1998 A
5716393 Lindenberg et al. Feb 1998 A
5716395 Myers et al. Feb 1998 A
5718159 Thompson Feb 1998 A
5718973 Lewis et al. Feb 1998 A
5720776 Chuter et al. Feb 1998 A
5723004 Dereume et al. Mar 1998 A
5725547 Chuter Mar 1998 A
5725549 Lam Mar 1998 A
5728131 Frantzen et al. Mar 1998 A
5733303 Israel et al. Mar 1998 A
5733325 Robinson et al. Mar 1998 A
5735892 Myers et al. Apr 1998 A
5735893 Lau et al. Apr 1998 A
5735897 Buirge Apr 1998 A
5741324 Glastra Apr 1998 A
5741325 Chaikof et al. Apr 1998 A
5747128 Campbell et al. May 1998 A
5749880 Banas et al. May 1998 A
5749894 Engleson May 1998 A
5749920 Quiachon et al. May 1998 A
5749921 Lenker et al. May 1998 A
5755772 Evans et al. May 1998 A
5755776 Al-Saadon May 1998 A
5766203 Imran et al. Jun 1998 A
5769882 Fogarty et al. Jun 1998 A
5769885 Quiachon et al. Jun 1998 A
5769887 Brown et al. Jun 1998 A
5772884 Tanaka et al. Jun 1998 A
5776142 Gunderson Jul 1998 A
5776161 Globerman Jul 1998 A
5776183 Kanesaka et al. Jul 1998 A
5780807 Saunders Jul 1998 A
5782789 Herweck et al. Jul 1998 A
5782838 Beyar et al. Jul 1998 A
5782904 White et al. Jul 1998 A
5782909 Quiachon et al. Jul 1998 A
5785679 Abolfathi et al. Jul 1998 A
5788626 Thompson Aug 1998 A
5789047 Sasaki et al. Aug 1998 A
5797951 Mueller Aug 1998 A
5798924 Eufinger et al. Aug 1998 A
5799384 Schwartz et al. Sep 1998 A
5800508 Goicoechea et al. Sep 1998 A
5800512 Lentz et al. Sep 1998 A
5800515 Nadal et al. Sep 1998 A
5800518 Piplani et al. Sep 1998 A
5800522 Campbell et al. Sep 1998 A
5800524 Borghi Sep 1998 A
5800526 Anderson et al. Sep 1998 A
5810870 Myers et al. Sep 1998 A
5810872 Kanesaka et al. Sep 1998 A
5814405 Branca et al. Sep 1998 A
5817102 Johnson et al. Oct 1998 A
5824037 Fogarty et al. Oct 1998 A
5824039 Piplani et al. Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5824042 Lombardi et al. Oct 1998 A
5824044 Quiachon et al. Oct 1998 A
5824046 Smith et al. Oct 1998 A
5824058 Ravenscroft et al. Oct 1998 A
5827289 Reiley et al. Oct 1998 A
5827310 Marin et al. Oct 1998 A
5827320 Richter et al. Oct 1998 A
5827321 Roubin et al. Oct 1998 A
5833651 Donovan et al. Nov 1998 A
5833707 Mcintyre et al. Nov 1998 A
5836964 Richter et al. Nov 1998 A
5836966 St. Germain Nov 1998 A
5840775 Howard, Jr. et al. Nov 1998 A
5843158 Lenker et al. Dec 1998 A
5843160 Rhodes Dec 1998 A
5843162 Inoue Dec 1998 A
5843164 Frantzen et al. Dec 1998 A
5843166 Lentz et al. Dec 1998 A
5843167 Dwyer et al. Dec 1998 A
5843170 Ahn Dec 1998 A
5843173 Shannon et al. Dec 1998 A
5843175 Frantzen Dec 1998 A
5853419 Imran Dec 1998 A
5855598 Pinchuk Jan 1999 A
5858556 Eckert et al. Jan 1999 A
5861027 Trapp Jan 1999 A
5871536 Lazarus Feb 1999 A
5871537 Holman et al. Feb 1999 A
5871538 Dereume Feb 1999 A
5873906 Lau et al. Feb 1999 A
5876432 Lau et al. Mar 1999 A
5891193 Robinson et al. Apr 1999 A
5904713 Leschinsky May 1999 A
5906619 Olson et al. May 1999 A
5906641 Thompson et al. May 1999 A
5910168 Meyers et al. Jun 1999 A
5910277 Ishino et al. Jun 1999 A
5911754 Kanesaka et al. Jun 1999 A
5916264 Von Oepen et al. Jun 1999 A
5919204 Lukic et al. Jul 1999 A
5922020 Klein et al. Jul 1999 A
5925061 Ogi et al. Jul 1999 A
5925075 Myers et al. Jul 1999 A
5931865 Silverman et al. Aug 1999 A
5935667 Calcote et al. Aug 1999 A
5939198 Howard, Jr. et al. Aug 1999 A
5944750 Tanner et al. Aug 1999 A
5948016 Jang Sep 1999 A
5954729 Bachmann et al. Sep 1999 A
5955016 Goldfarb Sep 1999 A
5957973 Quiachon et al. Sep 1999 A
5961545 Lentz et al. Oct 1999 A
5961546 Robinson et al. Oct 1999 A
5968068 Dehdashtian et al. Oct 1999 A
5968090 Ratcliff et al. Oct 1999 A
5972023 Tanner et al. Oct 1999 A
5972027 Johnson Oct 1999 A
5972441 Campbell et al. Oct 1999 A
5976155 Foreman et al. Nov 1999 A
5976179 Inoue Nov 1999 A
5976192 McIntyre et al. Nov 1999 A
5976650 Campbell et al. Nov 1999 A
5980530 Willard et al. Nov 1999 A
5980570 Simpson Nov 1999 A
5984955 Wisselink Nov 1999 A
5984956 Tweden et al. Nov 1999 A
5984964 Roberts et al. Nov 1999 A
5989287 Yang et al. Nov 1999 A
5993481 Marcade et al. Nov 1999 A
5993489 Lewis et al. Nov 1999 A
5997573 Quijano et al. Dec 1999 A
6001123 Lau Dec 1999 A
6004346 Wolff et al. Dec 1999 A
6004347 McNamara et al. Dec 1999 A
6004348 Banas et al. Dec 1999 A
6007575 Samuels Dec 1999 A
6015429 Lau et al. Jan 2000 A
6015431 Thornton et al. Jan 2000 A
6015432 Rakos et al. Jan 2000 A
6017362 Lau Jan 2000 A
6017364 Lazarus Jan 2000 A
6019778 Wilson et al. Feb 2000 A
6019779 Thorud et al. Feb 2000 A
6019787 Richard et al. Feb 2000 A
6022359 Frantzen Feb 2000 A
6024763 Lenker et al. Feb 2000 A
6025044 Campbell et al. Feb 2000 A
6027779 Campbell et al. Feb 2000 A
6027811 Campbell et al. Feb 2000 A
6030413 Lazarus Feb 2000 A
6030414 Taheri Feb 2000 A
6030415 Chuter Feb 2000 A
6036640 Corace et al. Mar 2000 A
6036702 Bachinski et al. Mar 2000 A
6036723 Anidjar et al. Mar 2000 A
6036724 Lentz et al. Mar 2000 A
6036725 Avellanet Mar 2000 A
6039754 Caro Mar 2000 A
6039758 Quiachon et al. Mar 2000 A
6042589 Marianne Mar 2000 A
6042605 Martin et al. Mar 2000 A
6042606 Frantzen Mar 2000 A
6045557 White et al. Apr 2000 A
6048484 House et al. Apr 2000 A
6051020 Goicoechea et al. Apr 2000 A
6053943 Edwin et al. Apr 2000 A
6059821 Anidjar et al. May 2000 A
6059823 Holman et al. May 2000 A
6060534 Ronan et al. May 2000 A
6063114 Nash et al. May 2000 A
6068626 Harrington et al. May 2000 A
6070589 Keith et al. Jun 2000 A
6074341 Anderson et al. Jun 2000 A
6075180 Sharber et al. Jun 2000 A
6077296 Shokoohi et al. Jun 2000 A
6077297 Robinson et al. Jun 2000 A
6077298 Tu et al. Jun 2000 A
6090128 Douglas Jul 2000 A
6093203 Uflacker Jul 2000 A
6096052 Callister et al. Aug 2000 A
6096070 Ragheb et al. Aug 2000 A
6098630 Papazoglou Aug 2000 A
6102918 Kerr Aug 2000 A
6102938 Evans et al. Aug 2000 A
6102940 Robichon et al. Aug 2000 A
6103172 Newman et al. Aug 2000 A
6106548 Roubin et al. Aug 2000 A
6110198 Fogarty et al. Aug 2000 A
6113628 Borghi Sep 2000 A
6117168 Yang et al. Sep 2000 A
6123722 Fogarty et al. Sep 2000 A
6124523 Banas et al. Sep 2000 A
6126685 Lenker et al. Oct 2000 A
6129756 Kugler et al. Oct 2000 A
6132457 Chobotov Oct 2000 A
6132459 Piplani et al. Oct 2000 A
6139572 Campbell et al. Oct 2000 A
6142973 Carleton et al. Nov 2000 A
6143014 Dehdashtian et al. Nov 2000 A
6143015 Nobles Nov 2000 A
6143016 Bleam et al. Nov 2000 A
6143021 Staehle Nov 2000 A
6143022 Shull et al. Nov 2000 A
6146389 Geitz Nov 2000 A
6146416 Andersen et al. Nov 2000 A
6146417 Ischinger Nov 2000 A
6149665 Gabbay Nov 2000 A
6149681 Houser et al. Nov 2000 A
6149682 Frid Nov 2000 A
6152944 Holman et al. Nov 2000 A
6152956 Pierce Nov 2000 A
6156063 Douglas Dec 2000 A
6156064 Chouinard Dec 2000 A
6159229 Jendersee et al. Dec 2000 A
6159237 Alt et al. Dec 2000 A
6159238 Killion et al. Dec 2000 A
6159239 Greenhalgh Dec 2000 A
6159565 Campbell et al. Dec 2000 A
6162243 Gray et al. Dec 2000 A
6162245 Jayaraman Dec 2000 A
6162246 Barone Dec 2000 A
6165210 Lau et al. Dec 2000 A
6165211 Thompson Dec 2000 A
6165212 Dereume et al. Dec 2000 A
6165213 Goicoechea et al. Dec 2000 A
6165214 Lazarus Dec 2000 A
6168610 Marin et al. Jan 2001 B1
6168614 Andersen et al. Jan 2001 B1
6168616 Brown, III Jan 2001 B1
6168617 Blaeser et al. Jan 2001 B1
6168618 Frantzen Jan 2001 B1
6168619 Dinh et al. Jan 2001 B1
6168620 Kerr Jan 2001 B1
6174326 Kitaoka et al. Jan 2001 B1
6183481 Lee et al. Feb 2001 B1
6183504 Inoue Feb 2001 B1
6187034 Frantzen Feb 2001 B1
6187036 Shaolian et al. Feb 2001 B1
6187054 Colone et al. Feb 2001 B1
6193745 Fogarty et al. Feb 2001 B1
6196230 Hall et al. Mar 2001 B1
6197046 Piplani et al. Mar 2001 B1
6197049 Shaolian et al. Mar 2001 B1
6200339 Leschinsky et al. Mar 2001 B1
6203550 Olson Mar 2001 B1
6203568 Lombardi et al. Mar 2001 B1
6203569 Wijay Mar 2001 B1
6203735 Edwin et al. Mar 2001 B1
6203779 Ricci et al. Mar 2001 B1
6210422 Douglas Apr 2001 B1
6210434 Quiachon et al. Apr 2001 B1
6210435 Piplani et al. Apr 2001 B1
6214038 Piplani et al. Apr 2001 B1
6214039 Banas et al. Apr 2001 B1
6217608 Penn et al. Apr 2001 B1
6221102 Baker et al. Apr 2001 B1
6224609 Ressemann et al. May 2001 B1
6231562 Khosravi et al. May 2001 B1
6235050 Quiachon et al. May 2001 B1
6235051 Murphy May 2001 B1
6238432 Parodi May 2001 B1
6240616 Yan Jun 2001 B1
6241759 Piplani et al. Jun 2001 B1
6245097 Inoue Jun 2001 B1
6245099 Edwin et al. Jun 2001 B1
6245100 Davila et al. Jun 2001 B1
6245101 Drasler et al. Jun 2001 B1
6245102 Jayaraman Jun 2001 B1
6248116 Chevillon et al. Jun 2001 B1
6251132 Ravenscroft et al. Jun 2001 B1
6251136 Guruwaiya et al. Jun 2001 B1
6254593 Wilson Jul 2001 B1
6254632 Wu et al. Jul 2001 B1
6258073 Mauch Jul 2001 B1
6258114 Konya et al. Jul 2001 B1
6258116 Hojeibane Jul 2001 B1
6261316 Shaolian et al. Jul 2001 B1
6261317 Inoue Jul 2001 B1
6264662 Lauterjung Jul 2001 B1
6264684 Banas et al. Jul 2001 B1
6267783 Letendre et al. Jul 2001 B1
6267834 Shannon et al. Jul 2001 B1
6270524 Kim Aug 2001 B1
6270525 Letendre et al. Aug 2001 B1
6270707 Hon et al. Aug 2001 B1
6273909 Kugler et al. Aug 2001 B1
6273910 Limon Aug 2001 B1
6273911 Cox et al. Aug 2001 B1
6280457 Wallace et al. Aug 2001 B1
6280466 Kugler et al. Aug 2001 B1
6280467 Leonhardt et al. Aug 2001 B1
6283991 Cox et al. Sep 2001 B1
6287315 Wijeratne et al. Sep 2001 B1
6287329 Duerig et al. Sep 2001 B1
6287330 Johansson et al. Sep 2001 B1
6287335 Drasler et al. Sep 2001 B1
6287336 Globerman et al. Sep 2001 B1
6290728 Phelps et al. Sep 2001 B1
6293966 Frantzen Sep 2001 B1
6293968 Taheri Sep 2001 B1
6293969 Chuter Sep 2001 B1
6296661 Davila et al. Oct 2001 B1
6302891 Nadal Oct 2001 B1
6302905 Goldsteen et al. Oct 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6302908 Parodi Oct 2001 B1
6303100 Ricci et al. Oct 2001 B1
6306141 Jervis Oct 2001 B1
6306145 Leschinsky Oct 2001 B1
6306164 Kujawski Oct 2001 B1
6306165 Patnaik et al. Oct 2001 B1
6312458 Golds Nov 2001 B1
6312460 Drasler et al. Nov 2001 B2
6312462 McDermott et al. Nov 2001 B1
6315791 Gingras et al. Nov 2001 B1
6319276 Holman et al. Nov 2001 B1
6319278 Quinn Nov 2001 B1
6319279 Shannon et al. Nov 2001 B1
6322587 Quiachon et al. Nov 2001 B1
6325819 Pavcnik et al. Dec 2001 B1
6325823 Horzewski et al. Dec 2001 B1
6325824 Limon Dec 2001 B2
6325825 Kula et al. Dec 2001 B1
6328762 Anderson et al. Dec 2001 B1
6331186 Wang et al. Dec 2001 B1
6331188 Lau et al. Dec 2001 B1
6331190 Shokoohi et al. Dec 2001 B1
6331191 Chobotov Dec 2001 B1
6334869 Leonhardt et al. Jan 2002 B1
6336937 Vonesh et al. Jan 2002 B1
6344044 Fulkerson et al. Feb 2002 B1
6344054 Parodi Feb 2002 B1
6344055 Shukov Feb 2002 B1
6346118 Baker et al. Feb 2002 B1
6346119 Kuwahara et al. Feb 2002 B1
6348065 Brown et al. Feb 2002 B1
6350277 Kocur Feb 2002 B1
6352553 Van der Burg et al. Mar 2002 B1
6352561 Leopold et al. Mar 2002 B1
6355055 Waksman et al. Mar 2002 B1
6355056 Pnheiro Mar 2002 B1
6355060 Lenker et al. Mar 2002 B1
6355063 Calcote Mar 2002 B1
6357104 Myers Mar 2002 B1
6358276 Edwin et al. Mar 2002 B1
6358284 Fearnot et al. Mar 2002 B1
6361637 Martin et al. Mar 2002 B2
6363938 Saadat Apr 2002 B2
6364856 Ding et al. Apr 2002 B1
6364904 Smith Apr 2002 B1
6368346 Jadhav Apr 2002 B1
6368347 Maini et al. Apr 2002 B1
6368355 Uflacker Apr 2002 B1
6371979 Beyar et al. Apr 2002 B1
6372136 Nakatsuka Apr 2002 B1
6375787 Lukic Apr 2002 B1
6379381 Hossainy et al. Apr 2002 B1
6379382 Yang Apr 2002 B1
6379392 Walak Apr 2002 B1
6383213 Wilson et al. May 2002 B2
6383214 Banas et al. May 2002 B1
6387119 Wolf et al. May 2002 B2
6387124 Buscemi et al. May 2002 B1
6391050 Broome May 2002 B1
6391052 Buirge et al. May 2002 B2
6395019 Chobotov May 2002 B2
6395022 Piplani et al. May 2002 B1
6395208 Herweck et al. May 2002 B1
6398803 Layne et al. Jun 2002 B1
6402779 Colone et al. Jun 2002 B1
6406489 Richter et al. Jun 2002 B1
6409749 Maynard Jun 2002 B1
6409750 Hyodoh Jun 2002 B1
6409754 Smith et al. Jun 2002 B1
6409756 Murphy Jun 2002 B1
6409757 Trout et al. Jun 2002 B1
6409761 Jang Jun 2002 B1
6413269 Bui et al. Jul 2002 B1
6416535 Lazarus Jul 2002 B1
6416536 Yee Jul 2002 B1
6416537 Martakos et al. Jul 2002 B1
6416538 Ley et al. Jul 2002 B1
6416539 Hassdenteufel Jul 2002 B1
6416542 Marcade et al. Jul 2002 B1
6419701 Cook et al. Jul 2002 B1
6423084 St. Germain Jul 2002 B1
6423089 Gingras et al. Jul 2002 B1
6423090 Hancock Jul 2002 B1
6425855 Tomonto Jul 2002 B2
6425898 Wilson et al. Jul 2002 B1
6428506 Simhambhatla et al. Aug 2002 B1
6428565 Wisselink Aug 2002 B1
6428566 Holt Aug 2002 B1
6428567 Wilson et al. Aug 2002 B2
6428569 Brown Aug 2002 B1
6428570 Globerman Aug 2002 B1
6428571 Lentz et al. Aug 2002 B1
6432129 DiCaprio Aug 2002 B2
6432131 Ravenscroft Aug 2002 B1
6432132 Cottone et al. Aug 2002 B1
6436104 Hoieibane Aug 2002 B2
6436133 Furst et al. Aug 2002 B1
6436134 Richter et al. Aug 2002 B2
6436135 Goldfarb Aug 2002 B1
6440165 Richter et al. Aug 2002 B1
6443941 Slepian et al. Sep 2002 B1
6443979 Stalker et al. Sep 2002 B1
6443981 Colone et al. Sep 2002 B1
6447501 Solar et al. Sep 2002 B1
6447522 Gambale et al. Sep 2002 B2
6451047 McCrea et al. Sep 2002 B2
6451050 Rudakov et al. Sep 2002 B1
6451051 Drasler et al. Sep 2002 B2
6451053 Dehdashtian et al. Sep 2002 B1
6454796 Barkman et al. Sep 2002 B1
6461381 Israel et al. Oct 2002 B2
6464720 Boatman et al. Oct 2002 B2
6464721 Marcade et al. Oct 2002 B1
6464722 Israel et al. Oct 2002 B2
6471718 Staehle et al. Oct 2002 B1
6471720 Ehr et al. Oct 2002 B1
6471721 Dang Oct 2002 B1
6471722 Inoue Oct 2002 B1
6475166 Escano Nov 2002 B1
6475208 Mauch Nov 2002 B2
6475236 Roubin et al. Nov 2002 B1
6475237 Drasler Nov 2002 B2
6475238 Fedida Nov 2002 B1
6475466 Ricci et al. Nov 2002 B1
6478807 Foreman et al. Nov 2002 B1
6478815 Alt Nov 2002 B1
6478816 Kveen et al. Nov 2002 B1
6482227 Solovay Nov 2002 B1
6485507 Walak et al. Nov 2002 B1
6485508 McGuinness Nov 2002 B1
6485509 Killion et al. Nov 2002 B2
6485511 Lau et al. Nov 2002 B2
6485513 Fan Nov 2002 B1
6485515 Strecker Nov 2002 B2
6485524 Strecker Nov 2002 B2
6488694 Lau et al. Dec 2002 B1
6488700 Klumb et al. Dec 2002 B2
6488701 Nolting et al. Dec 2002 B1
6488705 Schmitt et al. Dec 2002 B2
6491718 Ahmad Dec 2002 B1
6491719 Fogary et al. Dec 2002 B1
6494875 Mauch Dec 2002 B1
6494904 Love Dec 2002 B1
6494907 Bulver Dec 2002 B1
6494909 Greenhalgh Dec 2002 B2
6497722 Von Oepen et al. Dec 2002 B1
6497723 Starck et al. Dec 2002 B1
6500202 Shaolian et al. Dec 2002 B1
6500203 Thompson et al. Dec 2002 B1
6500204 Igaki Dec 2002 B1
6500532 Ruefer et al. Dec 2002 B1
6503271 Duerig et al. Jan 2003 B2
6506211 Doran et al. Jan 2003 B1
6508833 Pavcnik et al. Jan 2003 B2
6508834 Pinchasik et al. Jan 2003 B1
6514281 Blaeser et al. Feb 2003 B1
6517558 Gittings et al. Feb 2003 B2
6517571 Brauker et al. Feb 2003 B1
6517573 Pollock et al. Feb 2003 B1
6517574 Chuter Feb 2003 B1
6520983 Colgan et al. Feb 2003 B1
6520984 Garrison et al. Feb 2003 B1
6520986 Martin et al. Feb 2003 B2
6524334 Thompson Feb 2003 B1
6524335 Hartley et al. Feb 2003 B1
6524336 Papazolgou et al. Feb 2003 B1
6530765 Zdrahala et al. Mar 2003 B1
6530947 Euteneuer et al. Mar 2003 B1
6530950 Alvarado et al. Mar 2003 B1
6533806 Sullivan et al. Mar 2003 B1
6533807 Wolinsky et al. Mar 2003 B2
6533808 Thompson et al. Mar 2003 B1
6533811 Ryan et al. Mar 2003 B1
6537202 Frantzen Mar 2003 B1
6540778 Quiachon et al. Apr 2003 B1
6540780 Zilla et al. Apr 2003 B1
6547813 Stiger et al. Apr 2003 B2
6547814 Edwin et al. Apr 2003 B2
6547815 Myers Apr 2003 B2
6547817 Fischell et al. Apr 2003 B1
6548013 Kadavy et al. Apr 2003 B2
6551350 Thornton et al. Apr 2003 B1
6554857 Zilla et al. Apr 2003 B1
6554858 Dereume et al. Apr 2003 B2
6558414 Layne May 2003 B2
6558415 Thompson May 2003 B2
6562063 Euteneuer et al. May 2003 B1
6565597 Fearnot May 2003 B1
6569150 Teague May 2003 B2
6569190 Whalen, II et al. May 2003 B2
6569193 Cox et al. May 2003 B1
6572649 Berry et al. Jun 2003 B2
6575994 Marin Jun 2003 B1
6576009 Ryan et al. Jun 2003 B2
6579314 Lombardi et al. Jun 2003 B1
6582458 White et al. Jun 2003 B1
6589274 Stiger et al. Jul 2003 B2
6589275 Ivancev et al. Jul 2003 B1
6592614 Lenker et al. Jul 2003 B2
6602269 Wallace et al. Aug 2003 B2
6602280 Chobotov Aug 2003 B2
6602283 Doran et al. Aug 2003 B2
6605110 Harrison Aug 2003 B2
6607551 Sullivan et al. Aug 2003 B1
6613082 Yang Sep 2003 B2
6613083 Alt Sep 2003 B2
6613084 Yang Sep 2003 B2
6620190 Colone Sep 2003 B1
6626938 Butaric et al. Sep 2003 B1
6635079 Unsworth et al. Oct 2003 B2
6645240 Yee Nov 2003 B2
6652554 Wholey et al. Nov 2003 B1
6652570 Smith et al. Nov 2003 B2
6652573 Oepen Nov 2003 B2
6652575 Wang Nov 2003 B2
6652580 Chutter Nov 2003 B1
6656215 Yanez et al. Dec 2003 B1
6656506 Wu et al. Dec 2003 B1
6660030 Shaolian et al. Dec 2003 B2
6663662 Pacetti et al. Dec 2003 B2
6663663 Kim et al. Dec 2003 B2
6663664 Pacitti Dec 2003 B1
6663665 Shaolian et al. Dec 2003 B2
6663667 Dehdashtian et al. Dec 2003 B2
6669720 Pierce Dec 2003 B1
6669723 Killion et al. Dec 2003 B2
6669724 Park et al. Dec 2003 B2
6673102 Vonesh et al. Jan 2004 B1
6673103 Golds et al. Jan 2004 B1
6673106 Mitelberg et al. Jan 2004 B2
6673107 Brandt et al. Jan 2004 B1
6676667 Mareiro et al. Jan 2004 B2
6676695 Solem Jan 2004 B2
6679911 Burgermeister Jan 2004 B2
6685736 White et al. Feb 2004 B1
6689158 White et al. Feb 2004 B1
6689159 Hartigan et al. Feb 2004 B2
6692523 Holman et al. Feb 2004 B2
6694983 Hall et al. Feb 2004 B2
6695833 Frantzen Feb 2004 B1
6695875 Stelter et al. Feb 2004 B2
6695877 Brucker et al. Feb 2004 B2
6696666 Merdan et al. Feb 2004 B2
6699274 Stinson Mar 2004 B2
6699277 Freidberg et al. Mar 2004 B1
6702847 DiCarlo Mar 2004 B2
6702849 Dutta et al. Mar 2004 B1
6706064 Anson Mar 2004 B1
6709449 Camrud et al. Mar 2004 B2
6709455 Chouinard Mar 2004 B1
6712827 Ellis et al. Mar 2004 B2
6716238 Elliott Apr 2004 B2
6716239 Sowinski Apr 2004 B2
6719783 Lentz et al. Apr 2004 B2
6726712 Raeder-Devens Apr 2004 B1
6730119 Smalling May 2004 B1
6733521 Chobotov et al. May 2004 B2
6736839 Cummings May 2004 B2
6740111 Lauterjung May 2004 B1
6740114 Burgermeister May 2004 B2
6740115 Lombardi May 2004 B2
6743210 Hart et al. Jun 2004 B2
6743511 Dittrich et al. Jun 2004 B2
6746890 Gupta Jun 2004 B2
6752829 Kocur et al. Jun 2004 B2
6755855 Yurek et al. Jun 2004 B2
6758858 McCrea et al. Jul 2004 B2
6761733 Chobotov et al. Jul 2004 B2
6770086 Girton et al. Aug 2004 B1
6770087 Layne et al. Aug 2004 B2
6773453 Ravenscroft Aug 2004 B2
6773457 Ivancev et al. Aug 2004 B2
6776604 Chobotov et al. Aug 2004 B1
6776793 Brown et al. Aug 2004 B2
6786920 Shannon et al. Sep 2004 B2
6790227 Burgermeister Sep 2004 B2
6790230 Beyersdorf et al. Sep 2004 B2
6793672 Khosravi et al. Sep 2004 B2
6796999 Pinchasik Sep 2004 B2
6802849 Blaeser et al. Oct 2004 B2
6802856 Wilson Oct 2004 B2
6814753 Schmitt Nov 2004 B2
6818013 Mitelberg et al. Nov 2004 B2
6821292 Pazienza et al. Nov 2004 B2
6824558 Parodi Nov 2004 B2
6827726 Parodi Dec 2004 B2
6827731 Annstrong et al. Dec 2004 B2
6827735 Greenbeg Dec 2004 B2
6827737 Hill et al. Dec 2004 B2
6833004 Ishil et al. Dec 2004 B2
6841213 Parsonage et al. Jan 2005 B2
6843802 Villalobos et al. Jan 2005 B1
6849086 Cragg Feb 2005 B2
6858035 Whayne Feb 2005 B2
6860900 Clerc et al. Mar 2005 B2
6863685 Davila et al. Mar 2005 B2
6869443 Buscemi et al. Mar 2005 B2
6878160 Gilligan et al. Apr 2005 B2
6878161 Lenker Apr 2005 B2
6884260 Kugler et al. Apr 2005 B2
6899728 Phillips et al. May 2005 B1
6918925 Tehrani Jul 2005 B2
6918927 Bates et al. Jul 2005 B2
6923827 Campbell et al. Aug 2005 B2
6926732 Derus et al. Aug 2005 B2
6929659 Pinchuk Aug 2005 B2
6929709 Smith Aug 2005 B2
6939370 Hartley et al. Sep 2005 B2
6939374 Banik et al. Sep 2005 B2
6942689 Majercak Sep 2005 B2
6945989 Betelia et al. Sep 2005 B1
6945992 Goodson et al. Sep 2005 B2
6949120 Kveen et al. Sep 2005 B2
6962602 Vardi et al. Nov 2005 B2
6962603 Brown Nov 2005 B1
6964677 Osypka Nov 2005 B2
6974471 Van Schie et al. Dec 2005 B2
6974472 Hong et al. Dec 2005 B2
6981982 Armstrong et al. Jan 2006 B2
6989026 Richter et al. Jan 2006 B2
6994722 DiCarlo Feb 2006 B2
6997945 Germain Feb 2006 B2
6998060 Tomonto Feb 2006 B2
7001407 Hansen et al. Feb 2006 B2
7001419 DiCaprio et al. Feb 2006 B2
7001431 Bao et al. Feb 2006 B2
7011673 Fischell et al. Mar 2006 B2
7011674 Brenneman Mar 2006 B2
7022132 Kocur Apr 2006 B2
7022135 Zilla et al. Apr 2006 B2
7033389 Sherry Apr 2006 B2
7056325 Makower Jun 2006 B1
7056336 Armstrong et al. Jun 2006 B2
7056412 Henderson Jun 2006 B2
7066951 Chobotov Jun 2006 B2
7073504 Callister et al. Jul 2006 B2
7081129 Chobotov Jul 2006 B2
7081132 Cook Jul 2006 B2
7083642 Sirhan et al. Aug 2006 B2
7090693 Chobotov et al. Aug 2006 B1
7094255 Penn et al. Aug 2006 B2
7108715 Brown et al. Sep 2006 B2
7115140 Stoltze et al. Oct 2006 B2
7125464 Chobotov et al. Oct 2006 B2
7128754 Bolduc Oct 2006 B2
7128755 Su et al. Oct 2006 B2
7147455 Chobotov et al. Dec 2006 B2
7147660 Chobotov et al. Dec 2006 B2
7147661 Chobotov et al. Dec 2006 B2
7150758 Kari et al. Dec 2006 B2
7160318 Greenberg et al. Jan 2007 B2
7166125 Baker et al. Jan 2007 B1
7175651 Kerr Feb 2007 B2
7175652 Cook et al. Feb 2007 B2
7189256 Smith Mar 2007 B2
7192441 Sherry Mar 2007 B2
7223280 Anson et al. May 2007 B2
7226474 Iancea et al. Jun 2007 B2
7229470 Brian et al. Jun 2007 B2
7232459 Greenberg Jun 2007 B2
7244242 Freyman Jul 2007 B2
7273494 Rolando et al. Sep 2007 B2
7284399 Sisco Oct 2007 B1
7294147 Hartley Nov 2007 B2
7314484 Deem et al. Jan 2008 B2
7318835 Berra Jan 2008 B2
7338518 Chobotov Mar 2008 B2
7351256 Hojeibane et al. Apr 2008 B2
7425219 Quadri Sep 2008 B2
7452374 Hain et al. Nov 2008 B2
7465270 Li Dec 2008 B2
7485138 Fearnot et al. Feb 2009 B2
7491230 Holman et al. Feb 2009 B2
7491234 Palasis et al. Feb 2009 B2
7500988 Butaric et al. Mar 2009 B1
7510571 Spiridiglozzi et al. Mar 2009 B2
7520890 Phillips Apr 2009 B2
7520895 Douglas et al. Apr 2009 B2
7530988 Evans et al. May 2009 B2
7550004 Bahaler et al. Jun 2009 B2
7550005 Bates et al. Jun 2009 B2
7556645 Lashinski et al. Jul 2009 B2
7591843 Escano Sep 2009 B1
7597710 Obermiller Oct 2009 B2
7766954 Chobotov et al. Aug 2010 B2
7976575 Hartley Jul 2011 B2
8043356 Kolbel et al. Oct 2011 B2
8066755 Zacharias et al. Nov 2011 B2
8252036 Cartledge et al. Aug 2012 B2
20010014794 Moll Aug 2001 A1
20010029349 Leschinsky Oct 2001 A1
20010039445 Hall et al. Nov 2001 A1
20010041928 Pavcnik et al. Nov 2001 A1
20010044652 Moore Nov 2001 A1
20010049534 Lachat Dec 2001 A1
20020007193 Tanner et al. Jan 2002 A1
20020011684 Bahar et al. Jan 2002 A1
20020016626 DiMatteo et al. Feb 2002 A1
20020019659 Goicoechea et al. Feb 2002 A1
20020029051 Callister et al. Mar 2002 A1
20020032408 Parker et al. Mar 2002 A1
20020035395 Sigimoto Mar 2002 A1
20020040236 Lau et al. Apr 2002 A1
20020040237 Lentz et al. Apr 2002 A1
20020042644 Greenhalgh Apr 2002 A1
20020045931 Sogard et al. Apr 2002 A1
20020045933 Jang Apr 2002 A1
20020045934 Jang Apr 2002 A1
20020045935 Jang Apr 2002 A1
20020049487 Lootz et al. Apr 2002 A1
20020049490 Pollock et al. Apr 2002 A1
20020049493 Jang Apr 2002 A1
20020052627 Boylan et al. May 2002 A1
20020052644 Shaolin et al. May 2002 A1
20020052649 Greenhalgh May 2002 A1
20020055768 Hess et al. May 2002 A1
20020065552 Jayaraman et al. May 2002 A1
20020072792 Burgermeister et al. Jun 2002 A1
20020072793 Rolando et al. Jun 2002 A1
20020076542 Kramer et al. Jun 2002 A1
20020077692 Besselink Jun 2002 A1
20020082680 Stanley et al. Jun 2002 A1
20020082682 Barclay et al. Jun 2002 A1
20020082685 Sirhan et al. Jun 2002 A1
20020095208 Gregorich et al. Jul 2002 A1
20020096252 Lukic Jul 2002 A1
20020107561 Pinheiro Aug 2002 A1
20020116050 Kocur Aug 2002 A1
20020120321 Gunderson et al. Aug 2002 A1
20020120327 Cox et al. Aug 2002 A1
20020123790 White et al. Sep 2002 A1
20020123791 Harrison Sep 2002 A1
20020123796 Majercak et al. Sep 2002 A1
20020143387 Soetikno et al. Oct 2002 A1
20020147492 Shokoohi et al. Oct 2002 A1
20020151953 Chobotov et al. Oct 2002 A1
20020151956 Chobotov et al. Oct 2002 A1
20020156522 Ryan et al. Oct 2002 A1
20020161376 Barry et al. Oct 2002 A1
20020165603 Thornton et al. Nov 2002 A1
20020169497 Wholey et al. Nov 2002 A1
20020183826 Dorn et al. Dec 2002 A1
20020183827 Derus et al. Dec 2002 A1
20020188344 Bolea et al. Dec 2002 A1
20020188346 Healy et al. Dec 2002 A1
20020188347 Mathis Dec 2002 A1
20020193867 Gladdish, Jr. et al. Dec 2002 A1
20020193872 Trout et al. Dec 2002 A1
20020193873 Brucker et al. Dec 2002 A1
20020198585 Wisselink Dec 2002 A1
20020198587 Greenberg et al. Dec 2002 A1
20030004560 Chobotov et al. Jan 2003 A1
20030004565 Harnek et al. Jan 2003 A1
20030009212 Kerr Jan 2003 A1
20030014075 Rosenbluth et al. Jan 2003 A1
20030033001 Igaki Feb 2003 A1
20030040803 Rioux et al. Feb 2003 A1
20030050684 Abrams et al. Mar 2003 A1
20030068296 Ricci et al. Apr 2003 A1
20030074050 Kerr Apr 2003 A1
20030083736 Brown et al. May 2003 A1
20030088305 Van Schie et al. May 2003 A1
20030097170 Friedrich et al. May 2003 A1
20030116260 Chobotov et al. Jun 2003 A1
20030120263 Ouriel et al. Jun 2003 A1
20030120331 Chobotov et al. Jun 2003 A1
20030125797 Chobotov Jul 2003 A1
20030135256 Gallagher et al. Jul 2003 A1
20030135261 Kugler et al. Jul 2003 A1
20030176912 Chuter et al. Sep 2003 A1
20030191518 Spiridiglozzi et al. Oct 2003 A1
20030204236 Letort Oct 2003 A1
20030204244 Stiger Oct 2003 A1
20030212449 Cox Nov 2003 A1
20030220683 Minasian Nov 2003 A1
20030225453 Murch Dec 2003 A1
20040024446 Smith Feb 2004 A1
20040034407 Sherry Feb 2004 A1
20040044395 Nelson Mar 2004 A1
20040049212 Whayne Mar 2004 A1
20040049264 Sowinski et al. Mar 2004 A1
20040093055 Bartorelli et al. May 2004 A1
20040093064 Bosma May 2004 A1
20040093068 Bergen et al. May 2004 A1
20040093078 Moll et al. May 2004 A1
20040098096 Eton May 2004 A1
20040106974 Greenberg et al. Jun 2004 A1
20040116997 Taylor et al. Jun 2004 A1
20040138734 Chobotov et al. Jul 2004 A1
20040148008 Goodson et al. Jul 2004 A1
20040162607 Masroor Aug 2004 A1
20040167614 Anson Aug 2004 A1
20040176836 Chobotov Sep 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040215213 Dolan Oct 2004 A1
20040220655 Swanson et al. Nov 2004 A1
20040220664 Chobotov Nov 2004 A1
20040254625 Stephens Dec 2004 A1
20050033406 Barnhart et al. Feb 2005 A1
20050049674 Berra et al. Mar 2005 A1
20050049691 Mercile et al. Mar 2005 A1
20050075715 Borges et al. Apr 2005 A1
20050090804 Chobotov et al. Apr 2005 A1
20050090901 Studer Apr 2005 A1
20050154443 Linder et al. Jul 2005 A1
20050158272 Whirley et al. Jul 2005 A1
20050171593 Whirley et al. Aug 2005 A1
20050177222 Mead Aug 2005 A1
20050222669 Purdy Oct 2005 A1
20050228484 Stephens et al. Oct 2005 A1
20060009833 Chobotov et al. Jan 2006 A1
20060020319 Kim Jan 2006 A1
20060030921 Berra Feb 2006 A1
20060079952 Kaplan et al. Apr 2006 A1
20060136047 Obermiller et al. Jun 2006 A1
20060149364 Walak et al. Jul 2006 A1
20060161244 Seguin Jul 2006 A1
20060178732 Chobotov et al. Aug 2006 A1
20060186143 Argentine Aug 2006 A1
20060212112 Evans et al. Sep 2006 A1
20060224232 Chobotov Oct 2006 A1
20060233990 Humphrey et al. Oct 2006 A1
20060233991 Humphrey et al. Oct 2006 A1
20060287713 Douglas et al. Dec 2006 A1
20060292206 Kim et al. Dec 2006 A1
20070012396 Chobotov et al. Jan 2007 A1
20070016281 Melsheimer Jan 2007 A1
20070055347 Arbeferize Mar 2007 A1
20070100427 Perouse May 2007 A1
20070112413 Smith May 2007 A1
20070162106 Evans et al. Jul 2007 A1
20070167901 Herrig et al. Jul 2007 A1
20070203571 Kaplan et al. Aug 2007 A1
20070219627 Chu et al. Sep 2007 A1
20070239273 Allen Oct 2007 A1
20070244539 Lentz et al. Oct 2007 A1
20070276477 Lee et al. Nov 2007 A1
20070282369 Gilson et al. Dec 2007 A1
20080015687 Lashinski et al. Jan 2008 A1
20080027529 Hartley et al. Jan 2008 A1
20080051705 Von Oepen et al. Feb 2008 A1
20080058920 Kari Mar 2008 A1
20080114441 Rust May 2008 A1
20080114442 Mitchell et al. May 2008 A1
20080114443 Mitchell May 2008 A1
20080132995 Burgermeister et al. Jun 2008 A1
20080172119 Yamasaki et al. Jul 2008 A1
20080228255 Rust Sep 2008 A1
20090005854 Huang et al. Jan 2009 A1
20090036971 Humphrey et al. Feb 2009 A1
20090042796 Wallach et al. Feb 2009 A1
20090082841 Zacharias et al. Mar 2009 A1
20090082842 Glynn Mar 2009 A1
20090082844 Chobotov et al. Mar 2009 A1
20090082845 Chobotov et al. Mar 2009 A1
20090082846 Chobotov et al. Mar 2009 A1
20090082847 Zacharias et al. Mar 2009 A1
20090099649 Chobotov et al. Apr 2009 A1
20090132020 Watson May 2009 A1
20090132026 Martin et al. May 2009 A1
20090171431 Swanson et al. Jul 2009 A1
20090182406 Blaeser et al. Jul 2009 A1
20090198267 Evans et al. Aug 2009 A1
20090287145 Cragg et al. Nov 2009 A1
20090287290 Macaulay et al. Nov 2009 A1
20100114290 Rasmussen et al. May 2010 A1
20100161028 Chuter et al. Jun 2010 A1
20100211052 Brown et al. Aug 2010 A1
20100249908 Chau et al. Sep 2010 A1
20100305686 Cragg Dec 2010 A1
20100331958 Chobotov et al. Dec 2010 A1
20110130819 Cragg Jun 2011 A1
20110130820 Cragg Jun 2011 A1
20110130824 Cragg Jun 2011 A1
20110130825 Cragg Jun 2011 A1
20110130826 Cragg Jun 2011 A1
20110218609 Chobotov et al. Sep 2011 A1
20110238160 Molony Sep 2011 A1
20120016457 Chobotov et al. Jan 2012 A1
20120041543 Huang et al. Feb 2012 A1
20120130469 Cragg May 2012 A1
20120191174 Vinluan et al. Jul 2012 A1
20120197384 Lee et al. Aug 2012 A1
20130090715 Chobotov et al. Apr 2013 A1
20130268044 Parsons et al. Oct 2013 A1
20130268048 Watson et al. Oct 2013 A1
Foreign Referenced Citations (116)
Number Date Country
2438087 Mar 2001 CA
19624642 Jan 1998 DE
0646365 Apr 1995 EP
0714641 Jun 1996 EP
0775472 May 1997 EP
0792627 Sep 1997 EP
0808613 Nov 1997 EP
0819411 Jan 1998 EP
0878175 Nov 1998 EP
0943302 Sep 1999 EP
0997115 May 2000 EP
0480667 Apr 2001 EP
1093772 Apr 2001 EP
A 1138280 Oct 2001 EP
0808140 Dec 2001 EP
1163991 Dec 2001 EP
1212991 Jun 2002 EP
1266636 Dec 2002 EP
1380270 Jan 2004 EP
1415617 Apr 2004 EP
1 611 867 Jan 2006 EP
1611867 Jan 2006 EP
2 158 880 Mar 2010 EP
2158880 Mar 2010 EP
49 042773 Apr 1974 JP
3109404 May 1991 JP
5161665 Jun 1993 JP
6100054 Apr 1994 JP
09117511 May 1997 JP
18-126862 Jun 2006 JP
18-136382 Jun 2006 JP
1768154 Oct 1992 RU
1812980 Apr 1993 RU
2029527 Feb 1995 RU
1217402 Mar 1986 SU
1237201 Jun 1986 SU
1237202 Jun 1986 SU
1273077 Nov 1986 SU
1342511 Oct 1987 SU
1389778 Apr 1988 SU
1457921 Feb 1989 SU
1482714 May 1989 SU
1560134 Apr 1990 SU
1586718 Aug 1990 SU
1650127 May 1991 SU
1732964 May 1992 SU
WO 9100792 Jan 1991 WO
WO 9222604 Dec 1992 WO
WO 9313824 Jul 1993 WO
WO 9319804 Oct 1993 WO
WO 9403127 Feb 1994 WO
WO 9501761 Jan 1995 WO
WO 9503754 Feb 1995 WO
WO 9505132 Feb 1995 WO
WO 9509586 Apr 1995 WO
WO 9614095 May 1996 WO
WO 9614808 May 1996 WO
WO 9703624 Feb 1997 WO
WO 9707751 Mar 1997 WO
WO 9729716 Aug 1997 WO
WO 9748350 Dec 1997 WO
WO 9806355 Feb 1998 WO
WO 9820811 May 1998 WO
WO 9838947 Sep 1998 WO
WO 9841167 Sep 1998 WO
WO 9844870 Oct 1998 WO
WO 9844873 Oct 1998 WO
WO 9900073 Jan 1999 WO
WO 9926559 Jun 1999 WO
WO 9938455 Aug 1999 WO
WO 9943378 Sep 1999 WO
WO 9943379 Sep 1999 WO
WO 0010487 Mar 2000 WO
WO 0013613 Mar 2000 WO
WO 0042947 Jul 2000 WO
WO 0042948 Jul 2000 WO
WO 0044808 Aug 2000 WO
WO 0051522 Sep 2000 WO
WO 0067675 Nov 2000 WO
WO 0071179 Nov 2000 WO
WO 0105331 Jan 2001 WO
WO 0108599 Feb 2001 WO
WO 0115633 Mar 2001 WO
WO 0121108 Mar 2001 WO
WO 0130270 May 2001 WO
WO 0141675 Jun 2001 WO
WO 0156500 Aug 2001 WO
WO 0156504 Aug 2001 WO
WO 0158384 Aug 2001 WO
WO 0158387 Aug 2001 WO
WO 0166037 Sep 2001 WO
WO 0167993 Sep 2001 WO
WO 0174270 Oct 2001 WO
WO 0182836 Nov 2001 WO
WO 0236332 May 2002 WO
WO 0241804 May 2002 WO
WO 02078569 Oct 2002 WO
WO 02083038 Oct 2002 WO
WO 02100454 Dec 2002 WO
WO 03022180 Mar 2003 WO
WO 03053287 Jul 2003 WO
WO 03053288 Jul 2003 WO
WO 03094795 Nov 2003 WO
WO 03094799 Nov 2003 WO
WO 2004002370 Jan 2004 WO
WO 2004002371 Jan 2004 WO
WO 2004017866 Mar 2004 WO
WO 2004078065 Sep 2004 WO
WO 2005037076 Apr 2005 WO
WO 2005086942 Sep 2005 WO
WO 2006107562 Oct 2006 WO
WO 2008115678 Sep 2008 WO
WO 2009042796 Apr 2009 WO
WO 2009086200 Jul 2009 WO
WO 2011100367 Aug 2011 WO
WO 2012068175 Aug 2012 WO
Non-Patent Literature Citations (100)
Entry
US 6,413,270, 7/2002, Thornton et al. (withdrawn).
Blum et al. “Abdominal aortic aneurysms: preliminary technical and clinical results with transfemoral placement of endovascular self-expanding stent-grafts” Radiology 198(1):25-31 (1996). ;198(1):25-31 (1996).
Blum et al. “Endoluminal stent-grafts for infrarenal abdominal aortic aneurysms” N Engl J Med 336(1):13-20 (1997). ;336(1):13-20 (1997).
Campbell et al., “Balloon-Artery Interactions During Stent Placement: A Finite Element Analysis Approach to Pressure, Compliance, and Stent Design as Contributors to Vascular Injury”; 1999; American Heart Association; pp. 378-383.
Canero et al., “Optimal stent implantation: three-dimensional evaluation of the mutual position of stent and vessel via intracoronary echocardiography,” Computers in Cardiology, 261-264 (Sep. 1999).
Cooley, Denton A., Surgical Treatment of Aortic Aneurysms (Book), W.B. Saunders Company, West Washington Square, PA (1986).
Donayre, et al., “Fillable endovascular aneurysm repair”, Endovascular Today, p. 64-66, Jan. 2009.
Dumoulin C. et al., “Mechanical behavior modeling of balloon expandable stents.” Journal of Biomechanics, vol. 33, No. 11, pp. 1461-1470 (available online: Sep. 8, 2000).
Elger et al. “The Influence of Shape on the Stresses in Model Abdominal Aortic Aneurysms,” Transactions of the ASME 326:326-32 (1996).
Ernst “Current therapy for infrarenal aortic aneurysms” N Engl J Med 336(1):58-60 (1997).
Haimovitch, L. and Patierson, N., “Robust growth is forecast for endovascular repair of AAAs,” The BBI Newsletter, vol. 26, No. 5, pp. 113-144, (May 2003).
How et al. “Mechanical Properties of Arteries and Arterial Grafts,” Chapter 1 of Cardiovascular Biomaterials Hasting, G.W. (ed.) London; New York: Springer-Verlag, 1992 pp. 1-35.
Lakshmiraghavan, M. Mechanical Wall Stress in Abdominal Aortic Aneurysm: Towards the Development of a Clinical Tool to Predict Aneurysm Rupture. Submitted to the University of Pittsburgh, vol. 59/09-B of Dissertation Abstracts International p. 4948. 285 pages. (1998).
Mandai, S. et al. (1992). “Direct Thrombosis of Aneurysms with Cellulose Acetate Polymer. Part I: Results of Thrombosis in Experimental Aneurysms,” J. Neurosurgery 77:497-500.
Mirich et al., “Percutaneously Placed Endovascular Grafts for Aortic Aneurysms: Feasibility Study”, Radiology, 170/3:1033-1037 (1989); 1033-1037 (1989).
Moore et al. “Transfemoral endovascular repair of abdominal aortic aneurysm: results of the North American EVT phase 1 trial” J Vasc Surg 23(4):543-553 (1996). ;23(4):543-553 (1996).
Mower et al. “Stress Distributions in Vascular Aneurysms: Factors Affecting Risk of Aneurysm Rupture,” J. Surgical Research 55:151-61 (1993).
Parodi “Endovascular repair of abdominal aortic aneurysms and other arterial lesions” J Vasc Surg 21(4):549-557 (1995).;21(4):549-557 (1995).
Parodi et al., “Transfemoral intraluminal graft implantation for abdominal aortic aneurysms,” Ann. Vasc. Surg., 5(6):491-499 (1991).
Perry, M. D. and Chang, R. T., “Finite Element Analysis of NI-TI Alloy Stent Deployment,” Proceedings of the Second International Conference on SMST, Asilomar Conference Center, Pacific Grove CA. USA (1997).
Rogers et al., “Balloon-Artery Interactions During Stent Placement: A finite element analysis approach to pressure, compliance and stent design as contributors to vascular injury”, 1999 American Heart Association pp. 378-383.
Stern et al., “Interactive Definition of Endoluminal Aortic Stent Size and Morphology Based on Virtual Angioscopic Rendering of 3D Magnetic Resonance Angiography (MRA),” Cars. Computer Assisted Radiology and Surgery, Proceedings of the International Symposium on Computer Assisted Radiology and Surgery:176-180 (Jun. 1999).
The AneuRx® Stent Graft System Treatment for AAA brochure, “An Innovative Modular Approach for the Treatment of Abdominal Aortic Aneurysms (AAA),” Medtronic Ave, Inc. 1999.
The AneuRx® Stent Graft Treatment for TAA brochure, “An Endoluminal Solution for the Treatment of Descending Thoracic Aortic Aneurysms,” Medtronic, Inc. 1999.
U.S. Appl. No. 10/168,053, filed Jun. 14, 2002, entitled Inflatable Intraluminal Graft, by C. Murch.
Uflacker, R. and Robinson, J., “Endovascular treatment of abdominal aortic aneurysms: a review,” Eur. Radial., 11:739-753 (2001).
Verhagen “Latest AAA Innovations: The Rndurant Stent Graft System”, Veith Symposium Nov. 17, 2007.
Verhagen, Hence J.M. “Endurant Medtronic Endograft for EVAR: advantages & early experience”, Slides from Veith Symposium Presentation Nov. 22, 2008.
Volodos, N.L. et al. (1987). “New Balloon Catheter for Dilating Arteries and Installing Prosthesis During Distal Endoprosthetics With Self-Fixing Synthetic Prosthesis,” Thesis of VIII Symposium (Oct. 8-10, 1987), Abstract Only in English, four pages.
Volodos, N.L. et al. (1986) “Self-Fixing Synthetic Prostheisis for Endoprosthesis of Vessels,” Vestnik Khigurgii pp. 123-124, Abstract Only in English.
Volodos, N.L. et al. (1989). “Clinical Experience in Use of Self-Fixing Synthetic Prosthesis for Distal and Intraoperative Endoprosthestics of Aora and Iliac Arteries,” Theses of lxth All-Union Symposium (Oct. 2-3, 1989), Abstract only in English, four pages.
Vos, A.F.W. et al., “Endovascular Grafting of Complex Aortic Aneurysms with a modular Side Branch Stent Graft System in a Porcine Model”, Eur J Vasc Endovasc Surg, May 2004 vol. 27 492-497.
Web page, “Drug Eluting Stents—Why Use Drug Eluting Stents?;” Polymer Coatings Division; at URL http://www.lombardmedlcal.co.uk/lombard/pcde.why.html; Lombard Medical; printed Feb. 1, 2005.
Whitcher, “Simulation of in vivo loading conditions of nitinol vascular stent structures”, 1997, Elsevier Science Ltd., pp. 1005-1011.
Whitcher, F., “A Finite Element Treatment of the In-Vivo Loading Conditions of NITI Ad Vascular Stent and Graft Structures,” Proceedings of the Second International Conference on SMST, Asilomar Conference Center, Pacific Grove. CA, USA (1997).
Wisselink, W. et al. (2001). “Clipping of Inferior Mesenteric and Lumbar Arteries via Retroperitoneal Laparo-Endoscopic Approach as a Treatment of Persistent Endoleak” Chapter 18 In Endoleaks and Endotension, Veith, F.J. et al. eds. Marcel Dekker, Inc. pp. 211-220.
Extended European Search Report dated: Dec. 17, 2012 in European Application No. EP 08835032 filed: Oct. 3, 2008.
Extended European Search Report Mailed Jul. 27, 2010 in European Application No. 10005904.7 filed: Apr. 11, 2002 and published as: EP 2221023 on Aug. 25, 2010.
Extended European Search Report Mailed Dec. 16, 2009 in European Application No. 09175398.8 filed: Oct. 15, 2004 and published as: EP 2145607 on Jan. 20, 2010.
Extended European Search Report dated: Apr. 5, 2013 in European Application No. EP 08849544 filed: Nov. 13, 2008.
International Preliminary Report on Patentability mailed on Apr. 15, 2010 for International Application No. PCT/US2008/078846 filed on Oct. 3, 2008 and published as WO/2009/046372 on Apr. 9, 2009.
International Search Report and Written Opinion mailed on Jul. 30, 2009 for International Application No. PCT/US2008/078846 filed on Oct. 3, 2008 and published as WO/2009/046372 on Apr. 9, 2009.
International Preliminary Report on Patentability mailed on Apr. 8, 2010 for International Application No. PCT/US2008/077714 filed on Sep. 25, 2008 and published as WO/2009/042789 on Apr. 2, 2009.
International Search Report and Written Opinion mailed on: May 1, 2009 for International Application No. PCT/US2008/077714 filed on Sep. 25, 2008 and published as WO/2009/042789 on Apr. 2, 2009.
International Preliminary Report on Patentability mailed on May 27, 2010 for International Application No. PCT/US2008/083451 filed on Nov. 13, 2008 and published as WO/2009/064923 on May 22, 2009.
International Search Report and Written Opinion mailed on Jun. 30, 2009 for International Application No. PCT/US2008/083451 filed on Nov. 13, 2008 and published as WO/2009/064923 on May 22, 2009.
International Preliminary Report on Patentability mailed on Apr. 8, 2010 for International Application No. PCT/US2008/077727 filed on Sep. 25, 2008 and published as WO2009/042796 on Apr. 2, 2009.
International Search Report and Written Opinion mailed on Mar. 26, 2009 for International Application No. PCT/US2008/077727 filed on Sep. 25, 2008 and published as WO/2009/042796 on Apr. 2, 2009.
International Preliminary Report on Patentability mailed on Jul. 1, 2010 for International Application No. PCT/US2008/087831 filed on Dec. 19, 2008 and published as WO/2009/086200 on Jul. 9, 2009.
International Search Report and Written Opinion mailed on May 28, 2009 for International Application No. PCT/US2008/087831 filed on Dec. 19, 2008 and published as WO/2009/086200 on Jul. 9, 2009.
International Search Report and Written Opinion mailed on Oct. 31, 2011 for International Application No. PCT/US2011/024248 filed on Feb. 9, 2011 and published as WO/2011/100367 on Aug. 28, 2011.
International Search Report and Written Opinion mailed on Jul. 18, 2013 for International Application No. PCT/US2013/034654 filed on Mar. 29, 2013.
International Search Report and Written Opinion mailed on Jul. 18, 2013 for International Application No. PCT/US2013/034787 filed on Apr. 1, 2013.
Invitation to Pay Additional Fees and Partial Search Report dated: Apr. 25, 2013 for International Application No. PCT/US2011/060873 filed on Nov. 15, 2011 and published as WO/2012/068175 on Aug. 2, 2012.
International Search Report and Written Opinion mailed on Jun. 12, 2012 for International Application No. PCT/US2011/060873 filed on Nov. 15, 2011 and published as WO/2012/068175 on Aug. 2, 2012.
Office Action Response mailed: Jul. 18, 2011 in U.S. Appl. No. 12/245,620, filed Oct. 3, 2008 and published as: US2009/0099649 on Apr. 16, 2009.
Office Action mailed: Jan. 19, 2011 in U.S. Appl. No. 12/245,620, filed Oct. 3, 2008 and published as: US2009/0099649 on Apr. 16, 2009.
Office Action Response mailed: Nov. 12, 2010 in U.S. Appl. No. 12/245,620, filed Oct. 3, 2008 and published as: US2009/0099649 on Apr. 16, 2009.
Office Action mailed: May 14, 2010 in U.S. Appl. No. 12/245,620, filed Oct. 3, 2008 and published as: US2009/0099649 on Apr. 16, 2009.
Office Action Response mailed Oct. 24, 2012 in U.S. Appl. No. 11/861,739, filed Sep. 26, 2007 and published as: US2009/0082841 on Mar. 26, 2009.
Office Action mailed: Apr. 27, 2012 in U.S. Appl. No. 11/861,739, filed Sep. 26, 2007 and published as: US2009/0082841 on Mar. 26, 2009.
Office Action mailed: Sep. 14, 2011 in U.S. Appl. No. 11/861,739, filed Sep. 26, 2007 and published as: US2009/0082841 on Mar. 26, 2009.
Office Action Response mailed Jul. 15, 2011 in U.S. Appl. No. 11/861,739, filed Sep. 26, 2007 and published as: US2009/0082841 on Mar. 26, 2009.
Office Action mailed: Mar. 15, 2011 in U.S. Appl. No. 11/861,739, filed Sep. 26, 2007 and published as: US2009/0082841 on Mar. 26, 2009.
Office Action Response mailed Jan. 26, 2011 in U.S. Appl. No. 11/861,739, filed Sep. 26, 2007 and published as: US2009/0082841 on Mar. 26, 2009.
Office Action mailed: Aug. 26, 2010 in U.S. Appl. No. 11/861,739, filed Sep. 26, 2007 and published as: US2009/0082841 on Mar. 26, 2009.
Office Action Response mailed Jun. 14, 2010 in U.S. Appl. No. 11/861,739, filed Sep. 26, 2007 and published as: US2009/0082841 on Mar. 26, 2009.
Office Action mailed: Jan. 14, 2010 in U.S. Appl. No. 11/861,739, filed Sep. 26, 2007 and published as: US2009/0082841 on Mar. 26, 2009.
Office Action mailed: Jun. 7, 2012 in U.S. Appl. No. 11/861,756, filed Sep. 26, 2007 and published as: US2009/0082842 on Mar. 26, 2009.
Office Action mailed: Apr. 11, 2012 in U.S. Appl. No. 11/861,756, filed Sep. 26, 2007 and published as: US2009/0082842 on Mar. 26, 2009.
Office Action Response mailed: Mar. 20, 2012 in U.S. Appl. No. 11/861,756, filed Sep. 26, 2007 and published as: US2009/0082842 on Mar. 26, 2009.
Office Action mailed: Dec. 7, 2011 in U.S. Appl. No. 11/861,756, filed Sep. 26, 2007 and published as: US2009/0082842 on Mar. 26, 2009.
Office Action Response mailed: Oct. 21, 2011 in U.S. Appl. No. 11/861,756, filed Sep. 26, 2007 and published as: US2009/0082842 on Mar. 26, 2009.
Office Action mailed: Apr. 26, 2011 in U.S. Appl. No. 11/861,756, filed Sep. 26, 2007 and published as: US2009/0082842 on Mar. 26, 2009.
Office Action Response mailed: Apr. 5, 2011 in U.S. Appl. No. 11/861,756, filed Sep. 26, 2007 and published as: US2009/0082842 on Mar. 26, 2009.
Office Action mailed: Oct. 6, 2010 in U.S. Appl. No. 11/861,756, filed Sep. 26, 2007 and published as: US2009/0082842 on Mar. 26, 2009.
Office Action Response mailed: Sep. 1, 2010 in U.S. Appl. No. 11/861,756, filed Sep. 26, 2007 and published as: US2009/0082842 on Mar. 26, 2009.
Office Action mailed: Apr. 1, 2010 in U.S. Appl. No. 11/861,756, filed Sep. 26, 2007 and published as: US2009/0082842 on Mar. 26, 2009.
Office Action mailed on Jan. 30, 2013 in U.S. Appl. No. 12/747,499, filed on Sep. 7, 2010 and published as: US2010/0331958 on: Dec. 30, 2010.
Office Action Response mailed on Dec. 11, 2012 in U.S. Appl. No. 12/747,499, filed on Sep. 7, 2010 and published as: US2010/0331958 on: Dec. 30, 2010.
Office Action mailed on Jun. 18, 2012 in U.S. Appl. No. 12/747,499, filed on Sep. 7, 2010 and published as: US2010/0331958 on: Dec. 30, 2010.
Office Action Response mailed on May 17, 2012 in U.S. Appl. No. 12/747,499, filed on Sep. 7, 2010 and published as: US2010/0331958 on: Dec. 30, 2010.
Office Action mailed on Nov. 28, 2011 in U.S. Appl. No. 12/747,499, filed on Sep. 7, 2010 and published as: US2010/0331958 on: Dec. 30, 2010.
Office Action mailed: Mar. 13, 2012 in U.S. Appl. No. 11/861,731, filed Sep. 26, 2007 and published as: US2009/0082847 on Mar. 26, 2009.
Office Action Response mailed: Dec. 15, 2011 in U.S. Appl. No. 11/861,731, filed Sep. 26, 2007 and published as: US2009/0082847 on Mar. 26, 2009.
Office Action mailed: Jun. 21, 2011 in U.S. Appl. No. 11/861,731, filed Sep. 26, 2007 and published as: US2009/0082847 on Mar. 26, 2009.
Office Action Response mailed: May 23, 2011 in U.S. Appl. No. 11/861,731, filed Sep. 26, 2007 and published as: US2009/0082847 on Mar. 26, 2009.
Office Action mailed: Nov. 23, 2010 in U.S. Appl. No. 11/861,731, filed Sep. 26, 2007 and published as: US2009/0082847 on Mar. 26, 2009.
Office Action Response mailed on Oct. 12, 2010 in U.S. Appl. No. 11/861,731, filed Sep. 26, 2007 and published as: US2009/0082847 on Mar. 26, 2009.
Office Action mailed: Apr. 14, 2010 in U.S. Appl. No. 11/861,731, filed Sep. 26, 2007 and published as: US2009/0082847 on Mar. 26, 2009.
Office Action Response mailed: Jan. 4, 2010 in U.S. Appl. No. 11/861,731, filed Sep. 26, 2007 and published as: US2009/0082847 on Mar. 26, 2009.
Office Action mailed: Oct. 1, 2009 in U.S. Appl. No. 11/861,731, filed Sep. 26, 2007 and published as: US2009/0082847 on Mar. 26, 2009.
International Search Report and Written Opinion mailed on Jul. 18, 2013 for International Application No. PCT/US2013/034654, filed on Mar. 29, 2013 and published as WO 2013/151896 on Oct. 10, 2013.
International Search Report and Written Opinion mailed on Jul. 18, 2013 for International Application No. PCT/US2013/034787, filed on Apr. 1, 2013 and published as WO 2013/151924 on Oct. 10, 2013.
Office Action mailed on Sep. 18, 2013 in U.S. Appl. No. 11/861,828, filed on Sep. 26, 2007 and published as 2009-0082846 on Mar. 26, 2009.
Office Action Response dated: Jun. 30, 2014 in U.S. Appl. No. 13/297,219, filed Nov. 15, 2011 and published as: US2012/0191174 on: Jul. 26, 2012.
Office Action mailed: Jun. 19, 2014 in U.S. Appl. No. 12/245,620, filed Oct. 3, 2008 and published as: US2009/0099649 on Apr. 16, 2009.
Office Action mailed May 22, 2014 in U.S. Appl. No. 11/861,739, filed Sep. 26, 2007 and published as: US2009/0082841 on Mar. 26, 2009.
Office Action dated: Oct. 1, 2014 in U.S. Appl. No. 13/297,219, filed Nov. 15, 2011 and published as: US2012/0191174 on: Jul. 26, 2012.
Office Action dated: Mar. 28, 2014 in U.S. Appl. No. 13/297,219, filed Nov. 15, 2011 and published as: US2012/0191174 on: Jul. 26, 2012.
Related Publications (1)
Number Date Country
20130268044 A1 Oct 2013 US
Provisional Applications (1)
Number Date Country
61620362 Apr 2012 US